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Porphyrinoid biohybrid materials as an emerging
toolbox for biomedical light management
Vero´nica Almeida-Marrero, †a Eveline van de Winckel, †a
Eduardo Anaya-Plaza, a Toma´s Torres *abc and Andre´s de la Escosura *ab
The development of photoactive and biocompatible nanomaterials is a current major challenge of
materials science and nanotechnology, as they will contribute to promoting current and future
biomedical applications. A growing strategy in this direction consists of using biologically inspired hybrid
materials to maintain or even enhance the optical properties of chromophores and fluorophores in
biological media. Within this area, porphyrinoids constitute the most important family of organic
photosensitizers. The following extensive review will cover their incorporation into diﬀerent kinds of
photosensitizing biohybrid materials, as a fundamental research eﬀort toward the management of light for
biomedical use, including technologies such as photochemical internalization (PCI), photoimmunotherapy
(PIT), and theranostic combinations of fluorescence imaging and photodynamic therapy (PDT) or
photodynamic inactivation (PDI) of microorganisms.
1. Introduction
1.1. Light-induced nanomedicine
The use of nanotechnology for medical purposes (i.e., nano-
medicine) has grown exponentially over the past few decades,
as it is expected to enable more site-specific, eﬃcient and
personalized healthcare.1,2 Nanostructured materials present
numerous advantages for application in diﬀerent areas of bio-
medicine, including the design and development of nanodrugs,
multimodal imaging agents, and eﬃcient and selective drug
delivery systems.3,4 A straightforward approach towards these
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global goals involves the use of theranostics, which comprise
the inclusion of therapeutic and diagnostic functions within a
single nanostructure. Optical methods for imaging and therapy
are becoming indispensable in this respect, because they allow
tuning both kinds of functions through designed interactions
of the theranostic agent with light.5 Achieving an optimal
management of light therefore represents a great challenge in
biomedicine, which will pave the way to new promising medical
technologies in the near-future.
The human knowledge about how light can be employed
with a therapeutic objective actually deepens its routes in ancient
civilizations, yet the scientific fundaments of phototherapy were
only recognized at the beginning of the twentieth century, when
the Danish physician Niels Finsen received the Nobel Prize in this
field.6 The concept of photodynamic action was introduced by
Oscar Raab, a medical student of Hermann von Tappeiner at the
University of Munich, also in the early 1900s.7 For a historical
perspective on photodynamic therapy see ref. 8, where further
information about the following milestones can be found. The
modern explosion of interest in photosensitizing molecules
(i.e., photosensitizers, PS) for cancer treatment began around
the 1960s, when Lipson and coworkers described the tumor
accumulation of a haematoporphyrin derivative (HpD, a mix of
monomers, dimers and oligomers, developed by S. Swartz) and
its use in the photodetection of tumors. A significant break-
through happened in 1975, when T. Dougherty and colleagues
reported that the administration of HpD, together with a local
irradiation with red light, completely eradicates mammary tumor
growth in mice. In 1976, Kelly and co-workers initiated the first
successful clinical trial of HpD in patients with bladder cancer.
Further research into partially purified HpD for tumor therapy
resulted in the first clinically approved PS, Photofrin. In 1993
Photofrin received regulatory approval in Canada and subsequent
endorsement for specific clinical uses in the USA, various
European countries and Japan. Since then, many other photo-
sensitizing molecules have been approved and commercialized,9,10
including, among others, 5-aminolevulinic acid (ALA) for topical
diseases such as basal cell carcinoma, verteporfin (Visudyne) for
the treatment of age-related macular degeneration, and meta-
tetrahydroxyphenylchlorin (Foscan) or sulfonated aluminum
phthalocyanines (Photosens) for diﬀerent cancer types. An over-
view of PS can be found in ref. 9 and 10.
Regarding biomedical light management through the use of
PS, there are currently a number of possible applications, which
present diﬀerent degrees of development. The most common
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one is photodynamic therapy (PDT),11 a clinically approved
form of phototherapy in which PS become toxic to targeted
malignant and other diseased cells, through photoinduced
generation of singlet oxygen (1O2) and other reactive oxygen
species (ROS).12 When this kind of therapy is used to kill microbial
cells, including bacteria, yeasts, fungi and viruses, researchers also
refer to this treatment as photodynamic inactivation (PDI), anti-
microbial PDT (aPDT) or photodynamic antimicrobial chemo-
therapy (PACT).13 Herein we will use the acronym PDI. A very
promising, more specific form of PDT involves the combination of
standard PDT with immunotherapy of tumours.14 This treatment
option is referred to as photoimmunotherapy (PIT). Besides these
therapies, PS can also assist in the administration of other drugs,
e.g., in gene therapy, through the so-called photochemical inter-
nalization (PCI) technique.15,16 PCI is an intracellular delivery
method that increases the endosomal release of the drug by
co-administration of PS agents, which help in disrupting the
membranes of endocytic vesicles upon activation by light. On
the other hand, if PS convert the absorbed light into a fluorescence
emission, they can also be used for optical imaging. Compared to
other imaging modalities, fluorescence imaging presents various
advantages such as its non-invasive character, subcellular spatial
resolution, high temporal resolution, and high sensitivity in the
detection of biological structures at low concentration levels.17
Importantly, in the way to theranostic applications, all these
optical methods are susceptible to be combined with other,
non-optical therapeutic and imaging modalities.9,18
PS are generally classified as either porphyrinoids or non-
porphyrinoids.19,20 Due to the limited potency and various side
eﬀects associated with most non-porphyrinoid PS, their application
inmedicine has lagged considerably behind. Porphyrinoids, in turn,
are further classified as first-, second- and third-generation PS.21
First-generation PS include hematoporphyrin derivatives (HpD) and
porfimer sodium (Photofrin). A number of second-generation PS,
including porphyrin (Por), phthalocyanine (Pc), naphthalocyanine
(Nc), chlorin and boron dipyrromethene (BODIPY) derivatives, have
been developed to alleviate certain problems associated with the
first-generation ones, such as prolonged skin photosensitization
and suboptimal tissue penetration. Finally, third-generation
PS consist of second-generation PS covalently conjugated to
site-specific delivery agents and/or formulated with nanocarriers,
in order to obtain improved characteristics, such as less aggregation,
better solubility in physiological media and selective accumulation
within the targeted tissue.
Apart from the above-mentioned classification into three
generations, which does not always imply that third-generation
PS perform better than first- or second-generation PS, PS have
also been categorized according to their chemical structure
(Fig. 1). In particular, three broad categories are distinguished:
(i) Por, (ii) chlorins and (iii) synthetic dyes.22 The first category
consists of Por (Fig. 1a), such as the naturally prevalent HpD
and its derivatives, while the second one includes chlorophyll-
like substances that were discovered in photosynthetic systems
of plants (chlorins, Fig. 1b) or of bacteria and algae (bacterio-
chlorins, Fig. 1c). The latter are in fact reduced forms of Por,
and were found to possess equally great photosensitizing
properties. Among the category of synthetic dyes, in turn, Pc
(Fig. 1d) and its derivatives with extended conjugation, e.g., Nc
(Fig. 1e), represent the most prominent family, and have been
widely used in PDT.23–25 Corroles (Fig. 1f) are synthetic tetra-
pyrrolic macrocycles with chemical and photophysical properties
that are very similar to those of Por, yet only have three NH
groups in the inner core, which makes them stabilize high-valent
transition metal ions.26 Finally, BODIPY derivatives27 (Fig. 1g),
whose structure resembles half of a Por ring, are well-recognized
by their excellent fluorescence properties, which are commonly
employed in the context of bioimaging. All of the biohybrid
materials shown in this review involve the use of PS from any
of the above-mentioned families. As Pc and Por are the most
commonly used PS families in biomedical applications, they will
be normally discussed first in the different sections, in that order,
followed by the remaining possible PS families. For a more
detailed description of the chemical, photochemical and photo-
physical properties of these organic pigments, there are various
excellent reviews in the literature, some of them focused on PDT
and optical imaging.9,13,18 Besides, there exist other synthetic
porphyrinoid PS families that have not been included in the present
review, either because their use in biomedicine has been scarce,
such as for subporphyrins, subphthalocyanines, porphyrazines and
subporphyrazines,28 or because their incorporation into biohybrid
materials is very rare, such as for texaphyrins and other isomeric/
expanded porphyrin analogues. The chemistry29 and biomedical
applications30 of the latter families have actually been reviewed
recently.
1.2. Photosensitizing biohybrid materials
An important drawback of most organic PS systems, including
third-generation ones, is their low biocompatibility and unspecific
tissue accumulation, especially when they are not adequately
decorated with immunosuppressing moieties and targeting labels,
respectively. A recent strategy to tackle such important issues
consists of mimicking Nature, using biologically inspired hybrid
materials to maintain or even enhance the optical properties of PS
Fig. 1 Basic structures of the main porphyrinoid PS that have been used
to build up photoactive biohybrid materials, including (a) porphyrin, (b) chlorin,
(c) bacteriochlorin, (d) phthalocyanine, (e) naphthalocyanine, (f) corrole,
and (g) BODIPY derivatives.
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in physiological media. The notion of photosensitizing biohybrid
materials, which is new, will help in embracing many previous
experimental approaches regarding PS that could actually be
considered within the same conceptual framework. Research
eﬀorts towards combining the aqueous solubility, biocompatibility
and drug delivery properties of certain biomolecules and their
non-covalent assemblies with the biomedical functions of organic
PS comprise an emerging field with high growing potential,
nourished by intricate interactions between various scientific
disciplines such as physics, chemistry, biology and medical
technology. The results coming from such fields have never
been put together under a single perspective, as we do herein.
Embracing all those approaches from the same perspective is
also important to push forward the capacity of biomedicine for
light management, which will lead to crucial advances in the
form of fundamental knowledge and technological developments.
Concerning the chemistry and physics of biohybrid materials, for
example, endowing them with genuine optical and photochemical
features represents a successful approach toward novel opto-
electronic systems where the biological component induces
unprecedented behaviours. On the other hand, biomedicine
can certainly benefit from incorporating functional dyes into
diﬀerent biological architectures.
On these bases, herein we have reviewed the existing literature
about photosensitizing biohybrids, which could be classified into
diﬀerent groups depending on the nature of the biological
component in the biohybrid (Fig. 2). In particular, we have
distinguished between five categories of PS biohybrids, including
peptides, proteins (e.g., serum proteins, antibodies, protein cages),
nucleic acids, carbohydrates or liposome entities as biological
components in their structure. These categories actually
constitute the diﬀerent sections into which this review has
been structured (Sections 3–7). There are other kinds of bio-
molecules, such as hormones and folic acid, which have been
combined with PS to a lesser extent, yet their impact in
biomedicine may also be substantial and, thus, they have also
been covered in the present review (Section 8). The purpose of
this review is, in any case, not to cover all the work that has
been published so far, but to review the most important work
that has been carried out in such an extensive field. In particular,
we focus on hybrids that present demonstrated potential
for biomedical use, leaving aside approaches that combine
porphyrinoids with biomolecular species and assemblies for
other kinds of applications (e.g., optoelectronics, sensors, etc.),
which follow clearly different research trends, and would make
the present review just intractable.
Although from a wide perspective all the discussed biohybrids
serve to enhance the PS photochemical use in biological contexts,
the type of biomolecule that is employed somewhat biases
the application aimed in each case. Peptides, either natural
or synthetic, are for instance normally used to increase the PS
selectivity and aﬃnity for specific biological targets, which
makes them ideal PS delivery vehicles. Serum proteins facilitate
the transportation of PS through the body, improving the photo-
dynamic action and enhancing the intracellular accumulation
via receptor-mediated endocytosis. Antibodies are key to the
promising technology of PCI, while viral capsids and other
protein cages have a wide applicability in diﬀerent (bio-)nano-
technology applications. The merging of PS with oligonucleotides
has been utilized to perform photocatalytic oxidativemodifications
of DNA, to build up fluorescence-based diagnostic systems, and for
the onset of light-induced gene transfer. Concerning sugars, it is
diﬃcult to establish a clear association of each type of carbo-
hydrate with a specific type of application, as they are all being
commonly studied for PDT, PDI and theranostic applications.
Finally, liposomal drug formulations have been intensively
employed in clinical applications since the 1970s, and they are
considered the traditional way to formulate PS. In recent years,
more challenging goals have been pursued, like the development of
PS–liposome–antibody and PS–liposome–protein biohybrids, as
targeted drug delivery systems. All these concepts will be
reviewed in the following sections, where the reader will also
encounter appropriate references.
2. Biohybrid conjugation strategies
The term ‘bioconjugation’ refers to the chemical linkage of two
biomolecules, or of a biomolecule to one or more synthetic
functional labels.31 It actually represents a research field with
tremendous activity, mainly because methods for mild and site-
specific modification of proteins, nucleic acids, carbohydrates,
liposomes, etc., have an increasing impact on various aspects of
biotechnology, including the discovery of new biological inter-
actions, biochemical assays, and diagnostic and therapeutic
Fig. 2 Schematic representation of the photoactive biohybrids reviewed
in this review article. Porphyrinoids serve as photosensitizers, in combination
with six main types of biomolecules acting as nanocarriers. On these bases,
photosensitizing biohybrid materials are increasingly being employed in a
wide variety of light-induced biomedical applications.
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applications, among others. Such a perspective also applies, of
course, to the case of photosensitizing biohybrids and, as will
be shown along this review, the methods available to this end
are mostly the same as those utilized for other kinds of
bioconjugates. The references to such methods will be cited
when discussing specific examples in the subsequent sections,
yet a few guidelines concluded from the elaboration of this
review are shortly sketched in the next three paragraphs.
Photoactive biohybrids can be obtained by either covalent or
non-covalent association of PS with diﬀerent biomolecules. The
advantages of covalent approaches, as compared to supra-
molecular strategies, are the stability and the possibility of
achieving a well-defined localization of the PS in the biomolecule
structure, thanks to the use of modern biorthogonal and site-
specific reactions. The covalent approach also has disadvantages,
however, such as the requirement of having complementary
functional groups in both the biomolecule and the PS, which
demands in many occasions more complex designs and synthetic
routes. Supramolecular strategies, on the other hand, oﬀer a
wider choice in terms of the nature of the conjugation partner,
and so they grant the possibility of interaction with a diversity
of biological components. They also simplify, normally, the
design and synthesis of the hybrids. As drawbacks, non-covalent
biohybrids are usually less specific regarding the localization of
the PS on the biomolecule, and are not always stable under
physiological conditions, sometimes resulting in the leakage of
the PS before addressing the biological target.
The vast majority of publications concerning photoactive
biohybrids refer to species where the PS is linked to the biomolecule
via a covalent bond. In this way, PS have been conjugated to tumour
antigens, sugars, oligonucleotides, hormones, metabolites, cellular
signalling species, and, to a great extent, peptides and proteins.
Regarding the functional groups involved in the conjugation
reaction, the methodologies adopted so far can be divided into
two classes. The first class of methods are very straightforward,
involving the targeting of the amino or carboxylic groups
naturally present in most biomolecules (e.g., amino acids,
peptides, proteins, some carbohydrates, folic acid, etc.) through
amide formation with carboxylic or amino groups, respectively,
previously incorporated in the PS structure. Due to the ubiquity of
those functional groups in biology, these ‘‘traditional’’ conjugation
methods are usually not selective, and their eﬃciency is limited
under certain conditions, which often results in purification
problems. The second class of conjugation methods is based on
reactions with non-naturally occurring (abiotic) functionalities,
which are introduced into the PS and/or the biomolecule especially
for this purpose. From a chemical viewpoint, various groups of
reactions can be diﬀerentiated, such as metal-catalysed coupling
reactions, the formation of thioether and imine linkages, and
cycloaddition transformations, many of which can be performed
as ‘‘click’’ processes. A comprehensive overview of the main
covalent conjugation methods that have been utilized to connect
PS to diﬀerent biomolecules is provided in Table 1.
Supramolecular approaches, on the other hand, are less
abundant and more specific to the kind of biomolecule. Among
the types of existent non-covalent interactions, binding occurs
in many cases by a proper balance between hydrophobicity and
hydrophilicity in the PS structure (e.g., for the encapsulation of
PS in serum proteins or in the membranes of liposomes).
Electrostatic interactions are also commonly used to promote
the incorporation of charged PS into certain biomolecular
assemblies (e.g., protein cages, DNA or sugar nanostructures).
The intercalation of porphyrinoid PS into DNA double helixes
or quadruplexes is normally driven by a fine combination of
hydrogen bonding, electrostatic interactions and p–p stacking.
Finally, it is common to utilize biological recognition motifs
such as the biotin–(strept)avidin interaction, to produce protein
biohybrids. Due to the diversity of supramolecular strategies
toward PS biohybrids, however, they cannot be discussed in
detail in this section, and so they will be discussed when the
corresponding examples are mentioned in the text.
3. PS–peptide biohybrids
The bioconjugation of peptides to PS has received considerable
attention in the last few years, as it is an expedient method to
overcome issues generally associated with the use of hydrophobic
PS, including their scarce aqueous solubility and a strong
tendency to aggregation. Moreover, the utilization of natural
peptides, peptide analogues and newly designed synthetic
peptides can provide additional promising features such as a
better aﬃnity and selectivity for certain biological targets.32
3.1. Conjugation of PS to amino acids
The incorporation of amino acids (AA, the basic components of
peptides) into the structure of PS molecules is interesting
because it increases the aqueous solubility and biocompatibility
of the resulting hybrids. Although such hybrids cannot be
considered as peptide derivatives, and thus do not have the
potential to address specific biological targets, the possibility of
choosing between diﬀerent amino acid units enables tuning their
biological properties.
One of the roles that amino acids can play when linked to PS
is to promote their supramolecular organization into diﬀerent
kinds of aggregated structures. A lot of research has also been
focused on studies about molecular recognition between AA
and Por.33–36 This kind of supramolecular approach constitutes
an active research field but lies beyond the scope of the present
review, as the resulting ensembles currently lack any biomedical
applications.
As a widely explored conjugation strategy, amino acids can
be anchored to PS through amide bond formation, making use
of their carboxylic acid or amino functionalities to react with PS
compounds that bear the complementary functional group.37,38
Gu et al. explored the possibility of obtaining completely water-
soluble Zn(II)Pc derivatives with glycine units at the macrocycle
periphery.37 Drechsler et al. expanded the collection of Zn(II)Pc–AA
conjugates by anchoring two different AA units, phenylalanine and
serine, while they also investigated the use of less branched
alkyl or alkoxy chains as spacers, aiming at a reduction of the
aggregation tendency of these PS systems.38 The conjugates
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showed an excellent solubility and little aggregation in water,
but the phototoxicity assays showed poor results, and the
serine-containing hybrid was toxic in the dark. More successful
results were obtained by Haywood-Small et al., who incorporated
glycine, a-alanine, b-alanine, aminobutyric acid, aminovaleric acid
and aminocaproic acid at the periphery of Zn(II)Pc, in all cases
through sulphonamide formation.39 The phototoxicities shown by
these derivatives were very similar to that of tetrasulphonated
Zn(II)Pc, when tested in SiHa human cervical carcinoma cells.
Importantly, tumour tissues normally have a lower pH (pH 6.5)
Table 1 Main reaction types that have been used to prepare covalently linked PS biohybrid materials
Reaction type
Coupling unit
on the PS
Coupling unit on
the biomolecule Resulting conjugate Examples of biomolecules employed
Amide formation
Amino acids, short peptide sequences,
serum proteins, antibodies, nucleic acids,
carbohydrates, folic acid
Sulphonamide formation Amino acids, short peptide sequences, antibodies
Sonogashira coupling reaction Short peptide sequences, nucleic acids,steroid hormones
Buchwald–Hartwig reaction Short peptide sequences
Suzuki–Miyaura coupling reaction Short peptide sequences
Copper catalysed Huisgen [3+2]
cycloaddition Short peptide sequences, carbohydrates, antibodies
Isothiocyanate conjugation Serum proteins, antibodies, nucleic acids
O-Alkylation Nucleic acids
Ester formation Steroid hormones
Nucleophilic substitution Carbohydrates
Sulphonate ester formation Carbohydrates
Thiol–maleimide ‘‘click’’
chemistry
Antibodies, proteins, short peptide sequences,
liposomes
Axial substitution Nucleic acids, steroid hormones, carbohydrates
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compared to blood and normal tissues (pH 7.4).40 Based on this
factor, Wang et al. further investigated if there is a positive
correlation between the pH-dependent behaviour of Pc–AA
conjugates and their PDT activity.41 In particular, they synthe-
sized a series of AA-substituted Zn(II)Pc compounds that,
depending on the tumour microenvironment, can change their
overall charge, from positive to negative. As a consequence of
that change, the conjugates showed a higher photodynamic
activity and cellular uptake.
AA have also been covalently linked to Por-based PS.
Ramaiah and co-workers, for example, synthesized a series of
conjugates of H2Por and Zn(II)Por with proline and tryptophan,
for the study of their photophysical properties, their potential
generation of 1O2, and their interaction with biologically relevant
metal ions.42 Meng et al., in turn, worked on the conjugation of
aminophenyl-H2Por with L-lysine, L-arginine and L-histidine for
PDI applications.43 One of the advantages of using these AA
residues is that they are cationic under slightly acidic conditions,
thus promoting a higher aﬃnity of the PS for microbial cells.
Moreover, they make the PS biocompatible while ensuring that it
remains resistant to degradation by proteases, which is an
important limitation of PS–peptide hybrids. In vitro experiments
using these PS biohybrids against MRSA, E. coli and P. aeruginosa
actually showed that increasing the number of AA residues linked
to the Por macrocycle increased the observed PDI efficacy, the
most effective photoinactivation effect being produced by the Por
derivative with four lysine moieties, which also exhibited a lower
dark toxicity.
Ding and co-workers also studied the antimicrobial eﬃcacy
of Lys-H2Por, in this case against diﬀerent strains of Acinetobacter
baumannii, showing good results both in vitro and in vivo.44 In a
diﬀerent approach, Serra et al. synthesized four H2Por–AA
conjugates with glycine, serine, tyrosine and methionine.45
Biological assays were performed in vitro, against tumoral
(HeLa) and non-tumoral (HaCaT) human cell lines. All the
PS biohybrids showed good photostability and were able to
generate 1O2 upon irradiation, while no dark toxicity was
observed for an incubation period of one day.
Regarding other PS families, examples of conjugation to amino
acids can be found in the literature. Water-soluble conjugates have
been synthesized with chlorin p6 as the PS and glutamic acid or
aspartic acid as amino acid units.46 The conjugate with aspartic
acid showed a higher phototoxicity against melanoma, compared
to, for example, verteporfin, with a lower cytotoxicity and a
multiple subcellular localization that favours cell death as a
consequence of PDT treatment (Fig. 3). In a similar way, lysine
and aspartic acid have been conjugated to chlorin e6 in diﬀerent
positions of the macrocycle, and the PDT eﬃcacy of the resulting
biohybrids has been tested in human carcinoma Hep2 cells,
showing diﬀerent results depending on the conjugation site.47
3.2. Conjugation of PS to short peptide sequences
Due to the small size of peptides (o50 AA residues), linking them
to PS represents a potent strategy for providing the resulting
hybrids with low immunogenicity and good tissue penetration
properties. Peptides can be either natural or synthetic, and they
can be chemically modified, allowing tuning of their interactions
with diﬀerent target molecules. Many functional peptide libraries
have actually been described in the literature, with diﬀerent
sequences and functions, oﬀering a versatile platform of delivery
agents to localize PS conjugates in diﬀerent kinds of cells and
tissues.48
Covalently linked PS–peptide biohybrids can be synthesized,
taking advantage of mild synthetic organic methodologies such
as amide49–53,77,78,81,85–87,89,91–93,95,97,104,105 or sulphonamide54
bond formation, palladium-catalysed cross-coupling reactions,55,56
click-chemistry reactions57–59,81,94 and isothiocyanate chemistry,60,82
among other strategies. Supramolecular approaches have also been
used toward self-assembled peptide nanofibers,61 nanodots,62
vesicles,63 light harvesting complexes,64 arrays65 or polymeric
micelles with a peptide-decorated surface,66 among others.67,68
In particular, Yan and co-workers successfully used such supra-
molecular approaches towards biomedical applications, through
peptide-tuned self-assembly of PS,69 or by use of dipeptide
hydrogels with incorporation of PS.70,71 The resulting supra-
molecular biohybrids, mostly employing chlorin e6, have been
extensively tested both in vitro (in MCF-7 cells) and in vivo (in
mice), confirming their potential use for different anticancer PDT
pplications. For further reference, this research group has
also published some good reviews about the supramolecular
complexation of photodynamic and photothermal agents with
peptides or proteins, resulting in new platforms for drug delivery
purposes.72,73 However, as the supramolecular approach has not
been as commonly directed towards biomedical research as the
covalent approach, the next paragraphs will be mostly focused on
covalent conjugates.
In general, most of the PS–peptide conjugates have been
applied to PDT, with the peptide units being responsible for the
targeting of specific receptors, whereas biosensing by fluorescence
and that by positron emission tomography (PET) are other
potential applications of PS–peptide conjugates. Regarding the
different PS that could be employed, a great number of the
discussed examples are related to Pc and Por; however, other PS
such as BODIPY and chlorins have also been employed. In the
next subsections the different applications of these PS–peptide
biohybrids will be discussed in detail, categorized as per specific
receptors they target.
3.2.1. Targeting of the epidermal growth factor receptor
(EGFR). One of the most targeted receptors in PDT is the EGFR.
Fig. 3 Structure of the aspartylchlorin p6 dimethyl ester derivative (1),
which has shown excellent phototoxicity against melanoma in mice.46
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This receptor is a member of the ErbB family of cell-surface
receptors for peptide ligands, and has an important role in
diﬀerent cellular processes related to cancerous disorders.74
Among all EGFR-targeting biomolecules reported in the
literature, two small peptides with sequences LARLLT75 (EGFR-L1)
and YHWYGYTPQNVI76 (EFGR-L2) are particularly attractive, due to
their low immunogenicity, good capacity of conjugation and high
EGFR targeting ability (Fig. 4a). Vicente and co-workers were the first
to synthesize various Zn(II)Pc–peptide biohybrids using both
previously mentioned peptide sequences (Fig. 4b).52 The studied
Zn(II)Pc–peptide conjugates were shown to bind the EGFR, and
their photodynamic activity was tested in the human carcinoma
cell lines A431 and Hep2, and in the human colorectal cell line
HT-29. The Zn(II)Pc–EGFR–L1 conjugates (2a and 2b) efficiently
targeted EGFR and were actually internalized. The reason for
this positive result could be the presence of cationic charges,
whereas the lower aqueous solubility of the uncharged Zn(II)Pc–
EGFR–L2 conjugate (3a) lowered its targeting ability. Importantly,
the Zn(II)Pc–EGFR–L1 conjugates 2a and 2b could also be used
as new imaging agents (Fig. 4c), taking advantage of the low
toxicity that they present.
In a diﬀerent approach, peptides with LARLLT (EGFR-L1)
and GYHWYGYTPQNVI (EGFR-L3) sequences have been linked
to mesoporphyrin IX, using one or two propionic side chains,
connected directly or through a triethylene glycol spacer.77
Cytotoxicity was tested in human Hep2 cells. The authors of this
work conclude that the nature of the peptide and the spacer
influences the targeting ability and cellular uptake. The conjugate
that showed a higher aﬃnity for EGFR was the one bearing two
EGFR-L1 sequences, with no triethylene glycol spacers. After that,
the synthesis of a BODIPY bearing an isothiocyanate group
allowed its conjugation with the same peptides.60 After studies
with human Hep2 cells that overexpress the EGFR, the BODIPY
conjugates showed a low toxicity, and their targeting ability was
much higher compared to that of the non-conjugated BODIPY.
Based on these results, the authors proposed the conjugates
as potential near-IR fluorescence imaging agents. Concerning
BODIPY compounds, a final example describes the conjugation
of these PS to a peptidomimetic capable of binding to HER2,
which belongs to the family of EGFR receptors.78 The cellular
uptake of the conjugate was studied by confocal fluorescence
microscopy, showing a clear interaction with the receptor and
the PS internalization in cells that overexpressed HER2.
3.2.2. Targeting of the gastrin-releasing peptide (GRP) and
integrin receptors. The GRP receptor and the integrin avb3 are other
types of biological targets overexpressed in tumours of diﬀerent
natures. In particular, they can be targeted by bombesin (i.e.,
a 14-AA peptide with the sequence pEQRLGNQWAVGHLM-NH2) or
arginine-glycine-aspartic acid (RGD) derivatives.79,80 Consequently,
in 2008, van Lier and co-workers were the first to synthesize
a bombesin–Pc conjugate to target the GRP receptor.54
To this end, they made use of tetrasulphonated Al(III)Pc (AlPcS4),
observing that the photodynamic efficacy in PC-3 human prostate
cancer cells had improved with conjugation. In 2017, Giuliana et al.
synthesized two additional conjugates composed of bombesin and
an asymmetric Zn(II)Por, linked to a chelator that allows metal
coordination, in order to target prostate cancer cells for PDT and
imaging applications.81 The preparation of such PS was carried
out by click chemistry and amide coupling reactions, yet
the compounds were obtained in very low yields and with a
laborious HPLC purification. In order to achieve higher yields,
the authors suggested that the choice of the PS might be a
critical point. Besides, bombesin has been linked to a BODIPY
in experiments carried out by Brizet et al., the resulting hybrid
being suitable for bimodal PET/optical imaging.82
The avb3 integrin, on the other hand, is a protein present in
many tumour cells, which is implicated in diﬀerent tumoral
processes such as tumour growth, angiogenesis and metastasis.
This protein is expressed in tumour endothelial cells, and it can
be recognized by the RGD triad. In this way, RGD peptides have
been used as blockers of integrins, in order to avoid tumoral
events.83,84 Chaleix et al. designed, for example, a procedure for
the synthesis of RGD-substituted Por.85 This method is based
on the linkage of H2Por bearing a carboxylic acid function at
their meso position and the RGD peptide through a solid phase
approach. The phototoxicity of the obtained conjugates was tested
in a K562 Human Chronic Myelogenous Leukaemia cell line,
Fig. 4 (a) Low-energy docked structures of EGFR-L1 (left) and EGFR-L2
(right) peptides with the EGFR receptor. (b) Structures of the Zn(II)Pc–
peptide conjugates prepared to target the EGFR receptor. (c) Fluorescence
images (exc. 630 nm/em. 700 nm) of nude mice bearing subcutaneous
tumour implants of A431 (top) or HT-29 (bottom) cancer cells at various
times following the administration of biohybrid 2b. Adapted with permission
from ref. 52. Copyright 2012 American Chemical Society.
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and compared to the activity of Photofrin II, demonstrating its
possible use in PDT. Cyclic RGD peptides have also been
conjugated to tetraphenylchlorin and protoporphyrin IX using
solid phase peptide synthesis (SPPS) as a chemical strategy,
showing interesting results of phototoxicity.86,87
Finally, in 2013, the synthesis of a series of Zn(II)Pc–bombesin
and Zn(II)Pc–RGD peptide conjugates (4a–4e) was reported by the
van Lier group, targeting both the GRP and integrin receptors
(Fig. 5).56 The resulting conjugates showed a good aqueous
solubility, and their photodynamic effects were evaluated in cell
lines that express GRP and integrin receptors at different levels.
The Zn(II)Pc–bombesin conjugate 4e showed promising results as
a dual fluorescence imaging probe and photodynamic agent.
In particular, this biohybrid could be used as a PS for PDT of
cancers where the GRP receptor is overexpressed, as such as
prostate, breast and lung cancers. In 2014, Lo and co-workers
published a different Zn(II)Pc–RGD peptide conjugate.57 In
particular, they covalently linked a Zn(II)Pc with a monomeric
cyclic Arg-Gly-Asp-D-Phe-Lys (cRGDfK) moiety, which is an avb3
integrin antagonist. The cellular uptake was higher in avb3
+
U87-MG human glioblastoma cells, which present a higher
expression of avb3 integrin, as compared with avb3
 MCF-7
human breast adenocarcinoma cells, with a lower avb3 integrin
expression.
3.2.3. Targeting of the gonadotropin releasing hormone
(GnRH) receptor. GnRH is a pituitary hormone, and its receptor
appears in diﬀerent reproductive tissues and tumours associated
with them.88 To target this receptor, in 2002 Koch and co-workers
synthesized two conjugates composed of protoporphyrin IX and
some GnRH analogues, an agonist and an antagonist, through
the reaction between a free amino group from the peptides and a
carboxylic group from the PS.89 The binding ability of the
conjugates to the receptor was lower than expected, however,
probably due to the steric eﬀects produced by the PS. Using a
pituitary gonadotrope cell line, phototoxicity studies were carried
out, showing that the binding of GnRH to protoporphyrin IX did
not aﬀect the conjugate phototoxicity.
About a decade later, in 2012, Huang and co-workers reported a
Zn(II)Pc–peptide biohybrid targeting the GnRH receptor.50 The
hybrid was able to photogenerate 1O2 as efficiently as the free
Zn(II)Pc, while phototoxicity and cellular uptake were more
pronounced in cell lines overexpressing GnRH receptors (MDA-
MB-231 and MCF-7), e.g., in human breast cancer cells, than in
normal ones. Moreover, it was demonstrated, through the use of
Cetrorelix (i.e., a GnRH blocker), that the GnRH receptor is
responsible for cellular uptake, e.g., in MCF-7 cells. These results
prove the covalent conjugation of Zn(II)Pc with GnRH analogues
as an excellent strategy to increase the selectivity for GnRH-
overexpressing cells or tissues.
3.2.4. Nuclear targeting. Nuclear localization signals (NLS)
are sequences of amino acids that proteins carry to be imported
to the cell nucleus.90 In 1999, the synthesis of some conjugates
composed of covalently linked chlorin e6 and a NLS peptide
was described, and confocal fluorescence microscopy confirmed
the PS localization in the cell nuclei of CHO and RIF-1 cell
lines.91 In 2012, Lo and co-workers synthesized a novel Zn(II)Pc
conjugate with a NLS peptide, through a protocol that combined
click chemistry and Fmoc-based SPPS,53 achieving good results
of cellular uptake and ROS generation in HT29 human colorectal
carcinoma cells. Sibrian-Vazquez et al. synthesized, in turn,
multimeric Por–NLS conjugates (5a–5f), carrying between two
and four NLS peptide moieties, linked to H2Por through PEG or
5-carbon spacers, located at the meso positions of the Por
macrocycle (Fig. 6).92 The uptakes of the conjugates were
different depending on the configuration of the NLS peptides
in the Por structure, and on the number of peptide units. The
conjugate carrying a sequence of three consecutive NLS linked
by a PEG group to the Por core (5a) showed the highest cellular
uptake and phototoxicity in human carcinoma HEp2 cells.
However, no correlation could be observed between the number
of NLS units and the cellular uptake. The phototoxicity observed
in most cases was actually low, which can be explained by an
inefficient delivery into the cytoplasm. This work was in any
case interesting as one of the few studies aiming to establish
structure–activity relationships for PS–peptide hybrid systems.
A diﬀerent example of conjugation of a NLS sequence to
H2Por was described by Kahl and co-workers.
93 In this case, the
conjugate was able to interact in vitro with low density lipoproteins
(LDL) (see Section 4.1), allowing the delivery of the PS into
tumorigenic cells overexpressing LDL receptors. Finally, as
another interesting example, the conjugation of NLS peptides
to BODIPY derivatives was carried out by De Borggraeve and
co-workers,94 through a copper catalysed azide–alkyne cyclo-
addition. Unfortunately, no nuclear localization was observed
for such hybrids.
3.2.5. Antimicrobial peptides. Currently, diﬀerent strategies
are being searched to discover new therapies against microbial
agents, in order to tackle the appearance of new forms of resistance
to classical antibiotic drugs. PDI oﬀers an excellent alternative in
this respect, and the conjugation with antimicrobial peptides could
certainly help in directing PS to specific target microorganisms.
In this direction, Dosselli et al. developed the conjugation
of both a cationic H2Por and a neutral porphycene to the N- and
Fig. 5 Structures, synthetic strategies and uses of Pc–peptide conjugates
for targeting the GRP and integrin receptors. Adapted with permission
from ref. 56. Copyright 2013 American Chemical Society.
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C-terminal ends of apidaecin, an antimicrobial peptide, following
diﬀerent synthetic strategies, which depend on the PS and the
peptide component.95 Conjugating cationic Por to apidaecin
resulted in promoting cellular uptake in Gram-negative bacteria,
together with a reduction in the minimum eﬀective dose.
Importantly, conjugation did not decrease the capacity of the
PS for 1O2 generation and fluorescence emission, in contrast to
the case for porphycene. Furthermore, the peptide ability to enter
into Gram-negative bacteria was lost in the porphycene hybrids.
From a diﬀerent point of view, Vendrell and co-workers
proposed the synthesis of conjugates composed of a fluorogenic,
BODIPY-containing tryptophan derivative. The incorporation of
this fluorogenic amino acid in short antimicrobial peptides (e.g.,
6) did not impair their selectivity for fungal cells, and enabled a
rapid and direct imaging of Aspergillus fumigatus directly in
human pulmonary tissue, using diﬀerent kinds of fluorescence
assays and without any washing steps (Fig. 7).96–98
3.3. Multiple peptide strategy
The multiple peptide strategy consists of conjugating multiple
peptides with diﬀerent functions to the samemolecule or material,
in the present case, to a PS.99 Such an approach allows the
enhancement of diﬀerent properties of the PS system, like the
binding to a specific cell type or the cellular uptake, among many
others. The use of bifunctional peptides, which contain aminimum
sequence for translocation across cellular membranes and a
signalling sequence to direct the movement of the molecule
from the cytoplasm to a desired organelle, forms an interesting
example of this strategy.100–102 In this direction, Vicente and
co-workers published a bifunctional peptide–Zn(II)Pc conjugate,
containing the bipartite NLS nucleoplasmin peptide sequence
and a fusogenic peptide sequence that corresponds to the human
immunodeficiency virus I transcriptional activator (HIV-1 Tat,
48–60).49 The presence of a short or long PEG-linker in the
conjugates was also explored. The conjugate with the longer
linker provoked a higher phototoxicity but, conversely, it presented a
lower fluorescence quantum yield.
Alternatively, Engelen et al. synthesized a conjugate composed
of a Por and two diﬀerent peptides, CS3 and ES7, which act as
thrombin inhibitors.103 In particular, the authors prepared
tetrakis( p-[aminomethyl]phenyl) H2Por, which carries four
amino groups in meso positions, allowing the incorporation
of the diﬀerent peptide fragments through an adequate protection/
deprotection strategy. The obtained PS hybrids could be used for
sensing and imaging the interaction between diﬀerent molecules
and thrombin. Also with a H2Por, Vicente and co-workers synthe-
sized conjugates, which contain cell penetrating peptides (CPP)
and NLS peptides, searching for an enhancement of their photo-
toxic and biological properties,104 yet no nuclear localization was
observed. In the same year, an additional study by the same group
explored the photodynamic activity and biodistribution of these
types of conjugates (7a–7e), in prostate cancer cells, obtaining good
results of phototoxicity and selective subcellular accumulation in
the lysosomes and in the endoplasmic reticulum (ER) (Fig. 8).105
Importantly, both these organelles are normally implicated in the
PDT-induced initiation of apoptosis, which explains at least in
part the good phototoxicity results observed for these biohybrids.
4. PS–protein biohybrids
4.1. Hybrids with serum proteins
A very common strategy to administer drugs into the blood-
stream is by association with diﬀerent serum proteins, such as
albumin and high and low density lipoproteins, which then act
as biological carriers. The association between these proteins
Fig. 6 (a) Structures of multimeric NLS–H2Por conjugates studied
by Vicente and co-workers. (b) Time-dependent uptake of H2Por–NLS
conjugates 5b (black), 5a (red), 5c (blue), 5d (orange), 5e (green), and 5f
(purple) at 10 mM by HEp2 cells. (c) Phototoxicity of H2Por–NLS conjugates
5b (black), 5a (red), 5c (blue), 5d (orange), 5e (green), and 5f (purple)
toward HEp2 cells using 0.5 J cm2 dose light. Adapted with permission
from ref. 92. Copyright 2010 Royal Society of Chemistry.
Fig. 7 (a) Structure of the highly stable and fluorogenic BODIPY–peptide
biohybrid 6. (b) Time-lapse high-resolution imaging of A. fumigatus upon
incubation with a cell membrane counterstain (red) and compound 6
(2 mM, green) for 0 min (i), 1 min (ii), 3 min (iii) and 10 min (iv). Scale bar,
2.5 mm. Adapted from ref. 97. Copyright 2016 Nature Publishing Group.
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and hydrophobic PS therefore also enhances their photodynamic
activity and intracellular accumulation by endocytosis.100 In this
section we review the literature about both covalent and supra-
molecular combinations of diﬀerent PS with serum proteins.
4.1.1. Hybrids with serum albumin. Out of all serum
proteins in the human plasma, human serum albumin (HSA)
is the most abundant one. This protein binds many diﬀerent
hydrophobic molecules, thus representing an eﬃcient drug
carrier. HSA is actually involved in several cellular processes,
including some that are characteristic of cancer.106 For this
reason, PS–albumin conjugates are of much interest for the
development of biomedical applications. There are in the
literature a lot of publications that explore the fundamental
interactions between PS and albumins.107–114 Such studies,
which comprise both physicochemical and biophysical insights,
represent an extensive field with the general aim of under-
standing how natural albumins present in the body can, upon
injection of bare PS, become PS carriers and deliver them at the
target site. However, as the present review deals with biohybrid
materials, herein we will focus on a different strategy, consisting
of using synthetic hybrids where the albumin is modified with
PS prior to biomedical use, in order to enhance their chemical
and biological features.
The first ones to take up this approach were van Lier and
co-workers, who synthesized both non-covalent and covalent
Pc–BSA (bovine serum albumin) hybrids in two successive
publications. The non-covalent hybrid consisted of Zn(II)Pc–BSA
in an 11 : 1 molar ratio.115 Two different models of tumour-
bearing mice were employed to study the biocompatibility and
tumour control capacity of this biohybrid. The same authors later
covalently coupled two water-soluble tetrasulphonated Al(III)Pc
derivatives to BSA, in a 9 : 1 molar ratio, via a spacer bearing a free
carboxylic acid group that can react with the free amines of the
BSA protein.116 Due to the possible aggregation of the Al(III)Pc
within the BSA pocket, the activities of these hybrids were
not so high.
Supramolecular complexes of BSA or HSA have also been
described with Si(IV)Pc compounds bearing cationic substituents
at their axial positions.117–119 In all cases, the photodynamic
activities of the hybrids were higher than that of the free
Si(IV)Pc. Importantly, PS aggregation in the protein cavity was
proven detrimental for the PDT efficacy, as it quenches the PS
excited state. Consequently, the most promising results were
obtained for a dicationic Si(IV)Pc that was, in contrast to the
others, completely water-soluble. Following these studies, other
examples of BSA/HSA–Pc conjugates have been described in the
literature.120–123 As an interesting case, a Zn(II)Pc was linked to
a bifunctional protein containing HSA and an amino-terminal
fragment of urokinase (ATF).124 ATF binds to the urokinase
receptor, which appears with high expression levels in tumoral
cells, and so this conjugate could serve as a dual-mode PDT and
imaging agent (Fig. 9a). Li et al. described, on the other hand, a
covalent hybrid of IR700DX, a commercially available Si(IV)Pc,
and HSA bearing tumour targeting RGD peptides, connected
through an oligoethylene glycol spacer.125 Phototoxicity studies
in ovarian cancer cells showed that cellular delivery with this
conjugate occurred via an endocytosis process. Moreover, this
multivalent biohybrid resulted in being highly specific towards
carcinogenic cells, while cells that did not express avb3 integrin
were not affected.
Concerning PS other than Pc, Lu et al. prepared BODIPY-
based hierarchical nanostructures by hydrogen bonding with
Mn(II) complexes, which in turn were bound to HSA by hydro-
phobic forces.126 In order to increase the biocompatibility and
tumoral selectivity of the resulting particles, they were conjugated
to PEG–folic acid derivatives. Under irradiation of red LED light,
these nanohybrids were capable of generating 1O2 and ROS, and
of acting as MR agents for imaging techniques. With chlorin e6,
similar theranostic approaches have been considered. Hu et al.,
for example, reported the synthesis and application of activatable
HSA–chlorin e6 assemblies that can be thermally modulated for
imaging and PDT action against cancer cells.127 Chlorin e6 was
linked to HSA using hydrophobic interactions and intermolecular
disulfide bonds, and the resulting hybrids showed promising
features such as tumour selectivity, programmed self-assembly
and controllable activation of their theranostic activity. Using a
similar approach, chlorin e6, among other PS, has also been
encapsulated in protein-based nanospheres consisting of HAS
and poly-L-lysine, using the electrostatic assembly strategy.128
Moreover, the said nanospheres were designed to selectively
release chlorin e6 upon a combination of multiple tumour
Fig. 8 Structures of bifunctional NLS/CPP peptide–H2Por conjugates
7a–7e and subcellular localization studies for conjugate 7b. (a and d) Red
fluorescence indicating the location of conjugate 7b. (b) Green fluorescence
indicating the location of lysosomes in cells from (a). (c) Overlay of (a) with (b).
(e) Blue fluorescence indicating the location of the ER in cells from (d).
(f) Overlay of (d) with (e). The degrees of the orange (c) or purple (f) colours
indicate the intensity of conjugate 7b and organelle co-localization in
individual cells. Scale bar, 25 mm. Adapted with permission of ref. 105.
Copyright 2008 American Chemical Society.
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related triggers, resulting in highly tumour-responsive PDT
treatment. Effectively, the hybrid nanospheres were proven to
be nontoxic in the dark and cytotoxic under irradiation in three
different cancerous cell lines, including HeLa, B16 and MCF-7.
As a diﬀerent concept, chlorin e6 has been linked to BSA and,
simultaneously, to polypyrrole nanoparticles, to form conjugates
with good PDT and photothermal therapy (PTT) eﬃciencies,
without dark toxicity.129 With Gd(III) labelling, the conjugates
could act as imaging agents, thus presenting multiple biological
applications. In 2017, Zhou et al. described the growth of Gd2O3
nanocrystals using the hollow cavity of albumin as a nanoreactor,
followed by a later carbodiimide-mediated coupling reaction
with chlorin e6.130 These systems were evaluated as magnetic
resonance imaging (MRI) agents for tumour localization,
PDT and PTT, with good results of cellular toxicity (Fig. 9b).
Finally, nanoparticles composed of pheophorbide a, BSA and
polyethylene glycosylated folate have been synthesized by Battogtokh
and Ko.131 The use of the pH-responsive cleavable cis-aconityl moiety
as a spacer between the PS and BSA allowed activating the hybrid
fluorescence intracellularly, while the presence of folate gave rise
to enhanced results of phototoxicity in cancer cells, compared to
conjugates without the folate targeting units. As an interesting
example, an Fe(II)Por has been conjugated to BSA, and at the
same time, the porphyrinoid was encapsulated in a covalent way
into the inner cavity of cyclodextrins (CD) to form complexes that
could act as oxygen carriers.132 This concept of encapsulation
of PS into the inner cavity of CD will be further discussed in
Section 6.
4.1.2. Hybrids with lipoproteins. There are diﬀerent examples
of naturally produced lipoprotein particles, the most common
groups being high-density lipoproteins (HDL), low-density lipo-
proteins (LDL) and very low-density lipoproteins (VLDL), among
others. These proteins are able to transport diﬀerent hydro-
phobic compounds. The use of LDL, in particular, has been a
widespread strategy in recent years for the construction of
biohybrid materials. LDL consist of a cholesteryl ester core,
surrounded by a shell of cholesterol and phospholipids, with a
copy of the apolipoprotein B100. The LDL receptor is over-
expressed in tumour cells, making these particles a good choice
as drug delivery carriers.133,134 However, most of this research
was published in the 90s and the first years of this century, and
has been reviewed extensively.100 Herein we thus only give a
general impression about this research line, while for a better
inspection of the topic we refer to the reading of such review
articles.
In order to link PS drugs to LDL, three main types of
methodologies can be employed, which include the PS covalent
linkage to the apolipoprotein, the introduction of the drug into
the protein core, and its non-covalent adsorption to the surface
of the lipoprotein. The most useful method is the last one,
which leads to stable conjugates that do not alter the LDL
transport properties.135 As a prominent recent example, Tang
et al. carried out PDT experiments using lactone-containing
fluorinated H2Por and Zn(II)Por derivatives 8a–8d, with conjugated
glucose moieties improving the affinity for LDL (Fig. 10).136
The association with LDL improved cellular uptake via an
LDL-dependent pathway, which in turn favored a selective
localization in the lysosomes. b-Lactonization at the Por macro-
cycle, on the other hand, increased the intracellular production
of ROS, having a positive effect on phototoxicity against HeLa
cells, through an apoptotic mechanism.
4.2. PS–antibody biohybrids
The preparation of hybrids between antibodies and PS has led
to the development of a completely new field, called photo-
immunotherapy (PIT), a term that was first coined in 1983.14 In
PIT, the PS imparts phototoxic properties to the hybrid, while
monoclonal antibodies (MAb) act as targeting molecules,
directing the PS to the desired cells or tissues. An important
aspect in the design of this kind of therapeutic agent is to
preserve both the antigenic specificity of the MAb and the
Fig. 9 Two examples of theranostic systems based on PS-containing HAS
biohybrids. (a) Strategy to use a bifunctional recombinant protein (ATF-HSA)
loaded with a Zn(II)Pc, for targeting the urokinase receptor (uPAR) and thus
treating uPAR-expressing tumour cells upon illumination. The PS is bound at
the fatty acid binding site FA1 of HAS. Reproducedwith permission from ref. 124.
Copyright 2014 Ivyspring. (b) Schematic representation of the use of albumin as
a nanoreactor for the synthesis of chlorin e6-loaded Gd2O3-albumin
nanoparticles as agents that enable MRI-guided cancer PDT treatments.
Reproduced with permission from ref. 130. Copyright 2017 Ivyspring.
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intrinsic photophysical properties of the PS in the hybrids. An
excellent and extensive review about diﬀerent conjugation
strategies of PS with antibodies has been recently published
and should be consulted for getting a deeper insight into this
topic.137 As a consequence, herein we only focus on the most
important and most recent examples, classifying them according
to the biological receptors that they are aimed to target.
4.2.1. Targeting of the epidermal growth factor receptor
(EGFR). As a precursor of this strategy, in 2009, a sulphonated
Ga(III) corrole derivative (Ga(III)Cor) was linked to a breast cancer-
targeted CPP (HerPBK10), with the aim of targeting HER2, thus
mimicking the role of anti-HER MAb, while acting as a dual-
functioning imaging and therapeutic agent (Fig. 11).138 The
in vivo targeted delivery of the protein–corrole complex actually
led to tumour cell death, which could be visualized by the intense
corrole red fluorescence.
The synthesis of PS–antibody conjugates, in turn, has become
of growing interest since Kobayashi and co-workers initiated the
field by describing two Si(IV)Pc–MAb conjugates based on the same
Si(IV)Pc compound, denoted IR700, with the resulting biohybrids
presenting super-enhanced permeability and retention (SUPR)
effects, upon activation by near-infrared irradiation.139 In the
first of a series of in vivo studies with IR700–MAb conjugates,
the authors made use of two different MAb targeting the
EGFR, namely panitumumab (directed against human EGFR 1
(HER-1)) and trastuzumab (directed against human EGFR 2
(HER-2)).140 The resulting conjugates were denoted Pan–IR700
and Tra–IR700, respectively (Fig. 12). About three IR700 molecules
were linked to each Mab in these conjugates, and no MAb
aggregation was observed. Cytotoxicity studies revealed that both
IR700–MAb conjugates exhibited the exceptional characteristic of
being active only when bound to the cell membrane, and not in
their free unbound form. Off-target phototoxicity, until now the
largest side effect generally encountered in PDT, was in this way
reduced or almost completely excluded. This inherent selectivity is
of vital importance for real therapeutic applications.
Importantly, since IR700 can be activated by near infrared
light of reasonably high wavelengths (lmax = 689 nm), the
technique can also be referred to as NIR-PIT. In a subsequent
publication by Kobayashi et al., it was demonstrated that
repeated administrations of NIR light could actually enhance,
even more, the eﬀect of the NIR-PIT.141 Another desirable
feature of PIT using IR700–MAb conjugates is that they emit
fluorescence upon activation, so before the PIT the hybrid can
be used to monitor the application of light and minimize the
exposure of the surrounding tissues. The success of IR700–MAb
conjugates has generated a lot of research to understand the
mechanism and rates of cell death caused by NIR-PIT. On the
other hand, apart from observing cell death, Kobayashi and
co-workers have also monitored the acute cytotoxic effects caused by
PIT with the use of different techniques such as bioluminescence,142
fluorescence lifetime imaging143 and 18F-FDG PET.144 Up to now,
Fig. 10 (a) Chemical structures of Por derivatives 8a–8d. (b) Confocal
images of HeLa cells treated with 2 mM 8b-Glu, 100 mg mL1 LDL and
0 mg mL1 heparin (top) or 5 mg mL1 heparin (bottom). Adapted with
permission from ref. 136. Copyright 2014 Royal Society of Chemistry.
Fig. 11 (a) Detection of Ga(III)Cor–HerPBK10 in vivo targeting and intra-
cellular trafficking. Live animal imaging of corrole fluorescence after the IV
delivery of either the Ga(III)Cor or targeted complex. The scheme on the
left indicates the whole body and tumour orientation of the mice in the
fluorescence images. (b) Images capturing the time course of corrole
circulation in mice after receiving the Ga(III)Cor–HerPBK10 hybrid. Arrows
in both (a) and (b) point to tumours. The Ga(III)Cor fluorescence is indicated
by blue-red pseudocolouring, with the fluorescence intensity represented
according to the colour bar on the right. Reproduced with permission
from ref. 138. Copyright 2009 National Academy of Sciences.
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NIR-PIT with Tra-IR700 as the PS has been successfully tested in
preclinical trials for the treatment of peritoneal ovarian cancer145
and lung metastases.146,147
Following this successful work, various examples have appeared
in the literature about Por conjugation to EGFR-targeting MAb.
Maruani et al. described in 2015 a PS–MAb conjugate composed of
trastuzumab and a water-soluble azide-containing H2Por.
148 In
particular, they chose a disulfide linker to modify the MAb with a
dibromopyridazinedione-strained alkyne, which was subjected to a
copper-free strain-promoted alkyne–azide cycloaddition (SPAAC)
reaction with the H2Por derivative. The obtained biohybrid showed
good results of phototoxicity, and a minimal dark toxicity, in
experiments with HER2+ cells. More recently, Oliveira and
co-workers synthesized a different H2Por–trastuzumab conjugate
to target HER2 in gastric cancer,149 and the PIT results were
promising, reducing side effects in cells that do not express
HER2. The accumulation of the conjugate in lysosomes could
actually be the reason for its higher phototoxicity. As the
last example, again using the SPAAC strategy, a water-soluble
aza-BODIPY has also been conjugated to trastuzumab.150 This
conjugate showed selectivity for HER2 receptors and has been
claimed as a potential candidate for in vivo imaging techniques.
4.2.2. Targeting of the carcinoembryonic antigen (CEA).
CEA belongs to the family of cell surface glycoproteins, and is
overexpressed in human colon carcinomas, among others, for
which it can be used as a tumour marker.151 On these bases, in
1996, Pereyre and co-workers described the synthesis of radioactive
In(III)Por, and their conjugation to BSA bearing anticarcino-
embryonic MAb (anti-CEA).152 After that, Kuroki and co-workers
published the bioconjugation of a MAb against CEA, F11-39, to a
Ga(III)Por-based PS, by converting the PS carboxyl groups into
succinimidyl esters.153 The authors evaluated the cytotoxic
eﬀect of the conjugate in combination with sonodynamic
therapy (SDT), which uses ultrasound irradiation, against CEA-
expressing human gastric cells, obtaining much better results
when applying SDT than with just visible light irradiation.
In a diﬀerent approach, Pe`legrin and co-workers described
the conjugation of the MAb 37A7, directed against CEA, to tetra-
sulphonated Al(III)Pc, using the sulpho-NHS activation strategy.154
In vitro and in vivo properties like immunoreactivity and photo-
cytotoxicity were tested to understand the potential use of these
conjugates in PDT. After that, a second paper was published
evaluating the potential role of internalisation of the PS on its
photoinduced cytotoxicity.155 A related study was published in
2005, covalently linking MAb 35A7, which is not internalised upon
binding CEA, to H2Por, making use of isothiocyanate chemistry.
Assays of in vitro photoinduced cell inhibition in SKOv3-CEA-1B9
cell lines showed that these conjugates were more eﬀective than
the free PS, but even better results were obtained working with
conjugates of MAb FSP 77 to the same H2Por, which target the
extracellular domain of the HER2 receptor, present in this cell line
and which is normally internalised.156 More recently, Vicente and
co-workers synthesized two Zn(II)Pc–antiCEA conjugates through
carbodiimide-mediated coupling reactions, targeting and labelling
human colorectal HT-29 cells with higher efficiency compared to
the free Zn(II)Pc.157 Finally, CEA targeting with MAb was reported
by Bouvet and co-workers, who synthesized an anti-CEA-IR700
conjugate that expressed an extensive tumour cell killing in
pancreatic cancer in mice.158
4.2.3. Targeting of the cluster of diﬀerentiation molecules.
In 2005, Boyle and co-workers focussed on the synthesis of a
Zn(II)Pc derivative absorbing and emitting in the 700–850 nm
range, which can be obtained by a selective choice of its peripheral
groups. Furthermore, this PS contained a single amine-reactive
isothiocyanate group suitable for conjugation with MAb, which
permits employing the obtained conjugates as luminescent
probes.159 To demonstrate this concept, the Zn(II)Pc was
conjugated to both the anti-CD146 and the anti-CD104 MAb,
which are tumour-associated antigens upregulated in different
cancers. Analysis of flow cytometry data showed excellent
selectivity of the conjugates for their respective targets, and a
very low degree of non-specific binding. The conjugates were
also demonstrated to be non-phototoxic at concentrations
higher than those generally used for imaging, making them
highly suitable for use in bioimaging applications. In a different
approach, H2Por have been conjugated to BSA/HSA proteins
and anti-CD104 Mab, taking advantage of the presence of an
N-hydroxysuccinimide activated ester group in the Por structure,
which reacts with the amino groups from Lys amino acid
residues.160 The phototoxicities of these conjugates were evaluated
in the human bladder cancer cell line UM-UC-3, with the
bioconjugation to anti-CD104 MAb yielding better results than
the conjugates with BSA or HSA.
4.2.4. Other types of antibodies. Apart from the PS–MAb
biohybrids discussed before, there are a few studies in the
Fig. 12 (a) Schematic representation of IR700–MAb conjugates, designed
and developed for use in PIT. (b) Target-specific tumour growth inhibition by
Pan-IR700 after PIT in A431 tumours. (c) Biodistribution of Pan-IR700. A431
tumours (from both sides of the dorsum) were selectively visualized with IR700
fluorescence as early as 1 day after injection of 300 mg of Pan-IR700. Adapted
with permission from ref. 140. Copyright 2011 Nature Publishing Group.
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literature that utilized other kinds of MAb for the same purpose.
Because the number of examples for each type is limited, and
they do not constitute an extensive research line on their own,
we include them in a single, common section.
In 1986, Yarmush and co-workers described the synthesis of
conjugates between chlorin-e6 and the MAb anti-Leu-1, which
targets T-cells.161 The conjugates were synthesized through
coupling of the chlorin to a dextran polymer, which was able
to bind the MAb supramolecularly. Phototoxicity studies in
HPB-ALL human T-leukemia cells showed an eﬀective production
of 1O2 and a high cellular selectivity. Alonso et al., in turn,
synthesized a series of water-soluble H2Por derivatives that bear
maleimide moieties with diﬀerent spacers. Such PS were coupled
by click reactions of the Por maleimide functionalities with
cysteine residues from the SIP(L19) MAb, which targets the
tumour neoangiogenesis marker EDB of fibronectin.162 Photo-
toxicity was evaluated in LM-fibroblasts, and the best results were
obtained with the conjugate that presented the longest and most
hydrophilic spacer. Finally, a diﬀerent example targeted GPC3,
which is a cell-surface protein overexpressed in hepatocellular
carcinoma (HCC), among others.163 Based on the knowledge that
YP7 is an anti-GPC3 MAb, Kobayashi and co-workers designed an
IR700–YP7 conjugate, testing it in GPC3 expressing cells and
tumour-bearing mice.164 The effectiveness of this GPC3-targeted
PIT could be increased by co-administering the nanoparticle
albumin-bound paclitaxel (nab-paclitaxel), increasing the drug
delivery and thus its therapeutic effect.
4.2.5. Antibody fragments. All PS–antibody conjugates
mentioned above were based on full size MAb. Full size MAb
allow getting a higher degree of labelling, because they present
a high number of residues with reactive functional groups for
conjugation. However, such a high loading of PS molecules
sometimes affects the immune-reactivity of the MAb, increasing
non-specific binding due to a longer serum half-life and decreasing
diffusion in tumours with a poor vascularisation.137 To overcome
these limitations, the use of antibody fragments represents a
possible improvement in the area of PIT.
There are some examples in the literature that explore this
strategy. Kobayashi and co-workers, for example, made use of
anti-prostate specific membrane antigen (PSMA) diabody (Db)
andminibody (Mb) components, and compared their eﬀectiveness
as PIT agents with that of the full size anti-PSMA MAb (IgG).165
Upon NIR irradiation in in vitro and in vivo experiments, PIT with
IgG–IR700, Mb–IR700 and Db–IR700 resulted in the death of
PMSA-positive cells. From biodistribution data of the different
conjugates, however, it became clear that Db–IR700 was char-
acterized by a significantly shorter time interval between injection
and tumour uptake. This advantageously enabled the possibility of
reducing the time interval between injection and NIR irradiation,
pointing out the utility of such an approach.
Boyle and co-workers conjugated MAb fragments to Por
derivatives through an elegant strategy that ensures the stability
of the hybrids.166 In particular, they functionalized two water-
soluble Zn(II)Por using azide–alkyne cycloaddition reactions.
In one case, the azide group was directly substituted onto the
Por ring (9a), whereas for the other conjugate a short OEG spacer
chain was used (9b), in order to study the possible reduction of
photodynamic activity by quenching of the PS excited state due to
the proximity to the MAb fragment (Fig. 13). For conjugation,
the authors used the antigen binding fragment (Fab) from
trastuzumab, which was first reduced with tris(2-carboxyethyl)-
phosphine to break the disulfide bridge, and the resulting
thiol-containing fragments (VL–CL–SH and VH–CH1–SH) were
reacted with a propargyl-containing dibromomaleimide. The
last step in their approach was to click this fragment with the
azide–Zn(II)Por derivatives 9a and 9b. Importantly, no difference
in phototoxicity between the two Fab–Zn(II)Por conjugates was
found, both of them showing very good selectivity for HER2+
cells, with no dark toxicity.
4.3. PS–protein cage hybrids
Hollow protein scaﬀolds such as ferritin and virus-like particles
(VLP) have been employed during the last two decades as
nanocarriers and nanoreactors, due to their ability to accommodate
diﬀerent kinds of materials, including synthetic polymers and
drugs, enzymes, inorganic nanoparticles and organic dyes, inside
their inner cavity.167,168 These protein cage architectures are precise
assemblies of protein subunits with a diversity of roles in Nature,
from nucleic acid storage and transport in viruses to iron
mineralization in ferritins. Importantly, not only the native cages
but also analogues obtained by functionalization of their inner
and outer surfaces, or of the interstitial protein environment,
have led to new hybrid materials for direct application in
materials synthesis, drug delivery, and catalysis. Among all these
possibilities, the present section will focus on research about the
incorporation of PS in diﬀerent protein cages, which can actually
be classified according to their natural origin.
4.3.1. PS biohybrids based on the cowpea chlorotic mottle
virus (CCMV) capsid. One of the most common protein cages
used in nanotechnology is the CCMV capsid. CCMV is a positively
charged, single-stranded RNA plant virus composed of 90 coat
protein (CP) dimers. In the native state, these CP dimers
Fig. 13 (a) Scheme of the novel conjugation strategy followed to produce
trastuzumab Fab fragments, through functional rebridging and click chemistry
with Zn(II)Por. (b) Chemical structures of employed Zn(II)Por 9a and 9b. Adapted
with permission from ref. 166. Copyright 2014 American Chemical Society.
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self-assemble into a T = 3 icosahedral capsid formed by 12
pentameric and 20 hexameric capsomers, with outer and inner
diameters of 28 and 18 nm, respectively.168,169 The inner cavity can
be utilized to host diﬀerent materials, through its disassembly into
CP dimers by changing the pH and ionic strength, followed by
reassembly in the presence of the cargo.170–172 Besides, other
protein cage architectures can be obtained (e.g., T = 1 and T = 2
capsids, with outer diameters of 18 and 22 nm, respectively),
when the reassembly process occurs at neutral pH and in the
presence of polyanionic templates.173
de la Escosura, Cornelissen and co-workers were the first to
describe the loading of tetrasulphonated Zn(II)Pc aggregates
inside CCMV-based VLP, following two diﬀerent strategies,
which led to obtaining T = 3 and T = 1 VLP.174 The UV-Vis
spectrum of encapsulated Zn(II)Pc exhibited changes compared
to the free Zn(II)Pc, and the resulting hybrid particles showed
their potential as PS carrier systems for PDT. Both kinds of VLP
were further studied by Luque et al., through cryo-electron
microscopy (cryo-EM) and atomic force microscopy.175 These
studies showed that, in the T = 3 VLP, the Zn(II)Pc molecules are
localized underneath the pores of the protein cage, while T = 1
VLP present in their interior a well-packed Zn(II)Pc nanosphere
of 10 nm diameter, this being the reason for their enhanced
mechanical properties (Fig. 14).
Other polyanionic Pc-based systems have been reported as
templates for the preparation of CCMV biohybrids. The same
group described the inclusion of two Zn(II)Pc and two Ru(II)Pc
dendritic compounds, functionalized with carboxylate dendrons
at their peripheral or axial positions, respectively.176 Despite the
encapsulation of all these dendritic Pc derivatives, the authors
demonstrated that those which present 16 negative charges are
the most eﬃcient templates for VLP assembly, as they match the
number of positively charged residues present in the N-termini
of each CP dimer.170 This result highlights the importance of
the template eﬀect in this kind of cooperative self-assembly
process. Moreover, UV-Vis spectra of the biohybrids showed no
significant changes in the Pc absorption when encapsulated,
ensuring that the photosensitizing properties remain intact
when compared to the Pc in solution, and demonstrating the
suitability of these biohybrids as PS agents. In a diﬀerent approach,
the hierarchical self-assembly of a monocationic Zn(II)Pc in
paramagnetic anionic micelles, which were subsequently encapsu-
lated into CCMV VLP, has led to a promising multimodal imaging
and theranostic agent.177 To this end, the anionic micelles were
formed by an amphiphilic Gd3+ complex. Interestingly, it is the
self-assembly of the micelles which triggers the self-assembly
of the VLP particles. This elaborate strategy aimed at avoiding
undesired aggregation of Zn(II)Pc molecules within the hybrid
ensemble, to preserve their fluorescence and photosensitizing
properties. Gd3+ complexes, in turn, are well-known MRI agents,
giving rise to a multimodal imaging biohybrid.
4.3.2. PS biohybrids based on the use of phages. A diﬀerent
virus that has been used to construct biohybrids with PS is the
MS2 phage. This virus is an icosahedral RNA bacteriophage,
with T = 3 architecture.178 Its structure, as in the case of CCMV,
can be assembled and disassembled reversibly, and so diﬀerent
kinds ofmolecules andmaterials, including PS, can be incorporated
in its capsid.
Cohen and Bergkvist, for example, reported the construction
of MS2 biohybrids loaded with ca. 80 cationic H2Por molecules
per capsid, via a nucleotide-driven packaging, and decorated on
the outer surface with aptamers that act as targeting moieties
for human breast cancer cells.179 As control, capsids that were
decorated with non-targeting nucleotide sequences did not
show any phototoxic eﬀect. This proves that the linkage of
DNA sequences to virus capsids can be extremely useful to
direct PS–VLP hybrids to different tumoral tissues. Stephanopoulos
et al. described, for instance, anMS2 biohybrid decorated with up to
180H2Por 10 units at the capsid’s inner surface (Fig. 15).
180 This was
achieved by linking the thiol corresponding to Cys87, located in the
inner cavity upon assembly, with the maleimide-modified 10 via the
thiol–maleimide ‘‘click’’ reaction. Furthermore, DNA aptamers
targeting protein tyrosine kinase 7 (PTK7) receptors on Jurkat
leukaemia T cells were grafted onto the capsid outside. As a
consequence, the selectivity shown by these biohybrids, with a
ratio of 20 copies of the aptamer per capsid, was very high, and
they also presented an excellent PDT activity.
Similarly, the P22 phage, which is another example of a
bacteriophage with an icosahedral capsid and, in this case,
double-stranded DNA as genomic material,181 has been used to
include porphyrinoid PS in its structure. In particular, Douglas
and co-workers encapsulated Mn(III)Por inside VLP–polymer
covalent hybrids, to be used as MRI contrast agents.182 To this
end, a mutant P22 phage was swollen by resuspension of the
protein pellet into PBS 100 mM and NaCl 50 mM, pH 7.6, and
subjected to polymerization within the capsid. Further modification
was achieved through EDC-mediated labelling of the amino-
containing polymer with NHS-modified Mn(III)Por.
4.3.3. PS biohybrids based on ferritin. Ferritins constitute
a family of iron storage proteins with ubiquitous distribution
amongmost of the life forms, with internal and external diameters
of 8 and 12 nm, respectively. Their natural predisposition to
mineralize a variety of minerals and metals within the cage empty
cavity (i.e., apoferritin (aFt)) and their well-known structural features,
such as their stability and the possibility of redesigning the interior,
are key values to their wide use in various fields of research,
including nanotechnology, biomedicine and materials science.183
Fig. 14 (a) Self-assembly of 10 nm Zn(II)Pc nanospheres within T = 1
CCMV VLP (diameter: 20 nm) and their cryo-EM 3D reconstruction.
(b) Encapsulation of Zn(II)Pc inside T = 3 CCMV VLP (diameter: 28 nm)
and cryo-EM 3D reconstruction. Reproduced with permission from
ref. 175. Copyright 2014 Royal Society of Chemistry.
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Two examples of Pc–ferritin hybrids have been described so
far. First, Zhen et al. reported a surface-modified aFt cage that
was loaded with hexadecafluoro-Zn(II)Pc, acting as a potent PS with
a high 1O2 quantum yield.
184 The importance of this approach
relies on the vehiculization and specific tumour targeting of this
highly hydrophobic PS with a high loading ratio. When tested with
U87MG subcutaneous tumour models, the biohybrid showed a
good tumour inhibition rate and a low toxicity to the skin and
other organs, resembling other safe and efficient carriers for PDT.
On the other hand, de la Escosura, Kostiainen and co-workers
described the hierarchical organization of aFt into the first photo-
active protein crystals (Fig. 16).185 The co-crystallization could be
achieved by the formation of a supramolecular complex between an
octacationic Zn(II)Pc (11) and a tetraanionic pyrene (PTSA), which
acted as a molecular glue between the anionic patches of the aFt
cage. The obtained ternary face-centered cubic packed cocrystals
were eﬃcient 1O2 producers upon irradiation, thus representing a
promising material for PDI applications and diagnostic arrays,
among other possible uses.
5. PS–nucleic acid biohybrids
Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)
constitute, along with proteins and carbohydrates, one of the
essential families of macromolecules for all known forms of
life. Both types of nucleic acids are assembled as chains of
(ribo)nucleotides, which in turn are composed of a nitrogenous
base (nucleobase), a five-carbon sugar (ribose or deoxyribose),
and at least one phosphate group. A nucleoside is defined as a
nucleotide without the phosphate group, thus consisting of the
nucleobase and the 5-carbon sugar. Oligonucleotides, on the
other hand, are oligomers of various nucleotides, forming short
DNA or RNA molecules. Aiming to take advantage of the
informational and biological properties of nucleic acids and
their components, PS molecules have been integrated into
biohybrid materials with nucleobases, nucleosides, nucleotides
or oligonucleotides as biological counterparts. Strictly speaking,
nucleobases, nucleosides and nucleotides lack the informational
capacity of DNA and RNA, but they can induce interesting self-
assembly behaviour in the corresponding PS biohybrids, which in
turn has an eﬀect on their properties in biological media.
Connecting PS to oligonucleotides with adequate sequences of
nucleobases, on the other hand, provides them real potential
to address specific biological targets, and thus constitutes a
diﬀerent, more elaborate approach, which will be reviewed in a
diﬀerent section. Regarding the methods of conjugation, a wide
variety of them is again available (Fig. 17), the most utilized ones
including Sonogashira coupling reactions,186,187 O-alkylation,188
amide formation,189,190,197 isothiocyanate chemistry,193 and axial
substitutions.194,195 For Por, there is a recent review by Stulz
describing covalent strategies for their conjugation with DNA,196
which can be easily extrapolated to the other PS types. Herein,
anyhow, we will mainly focus on the biomedical perspective of
this research line.
5.1. PS biohybrids with nucleobases, nucleosides and
nucleotides
Based on their structural similarity, PS–nucleobase, PS–nucleo-
side and PS–nucleotide conjugates will be discussed together,
as they also have common features regarding their properties
and functions. Their main interest relies on the fact that they
Fig. 15 (a) Construction of a multivalent cell-targeted PDT vehicle using
recombinant bacteriophage MS2. (b) Scheme of the inner-wall modification of
MS2 CP with H2Por 10. (c) Selective killing of Jurkat T cells in the presence of
erythrocytes. (Left) Live control cells. (Middle) Cells exposed to 7.2 nM 10–MS2
VLP at 0 1C, and then irradiated with 415 nm light for 20 min at room
temperature. Only the larger Jurkat cells are dead, as indicated by the trypan
blue stain. (Right) Positive control cells exposed to 30% ethanol before staining
to induce cell death. Scale bars: 100 mm. Adapted with permission from ref. 180.
Copyright 2010 American Chemical Society.
Fig. 16 Scheme of the followed hierarchical strategy toward photoactive
biohybrid crystals (11–PTSA–aFt). (a) Chemical structures of 11 and PTSA,
and their self-assembly into the tetracationic 11–PTSA supramolecular
complex. (b) Illustrations of the 12 nm sized aFt cage and its further
co-crystallization with the 11–PTSA complex driven by electrostatic inter-
actions. Adapted with permission from ref. 185. Copyright 2016 American
Chemical Society.
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can interact with nucleic acids, or with other molecules containing
complementary nucleobases, through hydrogen bonding inter-
actions. The first experiments of this kind date from 1993 for
Por197 and from 2000 for Pc.188 No biological experiments were
carried out for any of these examples, but their base-pairing
capacities were examined in different ways.
The first and only Zn(II)Pc–nucleobase biohybrid with a real
biomedical application was reported by Liu and co-workers, who
developed a Hg2+ sensor based on Zn(II)Pc–thymine conjugates.189
Aggregation and subsequent precipitation of the Zn(II)Pc was
induced by interaction of its thymine units with Hg2+, resulting
in a decrease of the PS absorption Q-band, and thus of the
concomitant fluorescence emission. Other examples of the use
of PS–nucleobase conjugates as sensors have been reported with
Por. In particular, Balaz and co-workers studied their dependency
on the presence of thymine or adenine, the number of nucleo-
bases, and the Por central metal.198 Linking adenine instead of
thymine produced a decrease in the limit of detection of Hg2+ in
water, while the combination of zinc as the central metal and
oligodeoxythymidine as the sensing unit showed the best results
toward this mercury cation. Cytosine-substituted Co(II)Por and
Zn(II)Por have been used, on the other hand, as nucleotide
receptors.192 Moreover, adenine and thymine have been linked
to H2Por, in order to study the interaction of the resulting hybrids
with nucleic acids and nucleosides.199 The authors concluded that
self-aggregation, due to p–p stacking between the PS and nucleo-
bases, has a big influence on the conjugates’ binding properties.
In 2013, the first Pc–nucleoside biohybrid with a biomedical
application was reported by Huang and co-workers.195 They
synthesized a series of novel Si(IV)Pc that are axially conjugated
with uridine and cytidine derivatives, and their photodynamic
activities were evaluated as a function of the nucleoside
employed. Due to its high cellular uptake and lack of aggregation,
the compound containing uridine showed the best PDT results.
Regarding nucleotides, conjugates of BODIPY with adenosine
triphosphate and gold nanoparticles have been used as detection
systems for adenosine, being able to discriminate between
adenosine and their analogues.200 In a diﬀerent scenario,
Hocek and co-workers reported in 2014 the synthesis of deoxy-
nucleoside triphosphate analogues labelled with a BODIPY unit,
through a flexible and short linker.186 The conjugates were used
as nucleotide monomers by polymerases in the synthesis of
DNA (Fig. 18). The BODIPY fluorescence was not quenched in
the resulting DNA duplexes, thus serving as a labelling method
for this biopolymer. Using the same concept, two years later,
Dziuba et al. described the use a rotational BODIPY–nucleotide
hybrid as a sensor of DNA interactions in vitro and in vivo, further
stressing the great potential of such a strategy for labelling
genetic material.187
5.2. PS–oligonucleotide biohybrids
Although there exist a number of articles related to the combination
of PS and nucleic acid monomers, as shown in the previous section,
themost interesting properties emerge from their combination with
biologically active nucleic acids. Indeed, there are diﬀerent possible
uses of PS–oligonucleotide hybrids, which include photocatalytic
processes for modification of DNA, the development of DNA-based
fluorescence diagnostic systems, light-induced gene transfer,
and G-quadruplex recognition. These applications are discussed
separately in the following subsections.
5.2.1. Photocatalytic oxidative modification of DNA. The
modification of DNA using PS through various strategies has
been reported in the literature. In 1996, He´le`ne and co-workers
described conjugates of two diﬀerent chlorin derivatives with
oligodeoxynucleotide components, through carboxylic or aldehyde
groups linked to the 30-activated phosphate of the terminal
nucleotides.201 Under red light irradiation, the conjugates were
able to produce damage to specific sequences of DNA. One year
after, Li et al. reported the solid-phase synthesis of H2Por–
oligonucleotide conjugates for the same purpose.202 Fedorova
and co-workers published a series of MPc (M = Zn(II), Al(III),
Co(II)) conjugated with oligonucleotides that direct the Pc to the
selected complementary sequence on the DNA target.190 The
Zn(II)Pc and Al(III)Pc conjugates were able to produce 1O2, while in
the case of Co(II)Pc DNA oxidation was promoted by molecular
oxygen and the production of ROS species. On these bases, these
systems could be very useful in genetic regulation and in the
treatment of cancer.
A very promising research line relates to photoinduced DNA
interstrand cross-linking, induced in furan-modified genetic
material by a PS irradiated with light of adequate wavelength.203
The production of 1O2 close to the furan moieties leads to their
rupture, generating reactive intermediate species that result in
Fig. 17 Scheme of the most important strategies for chemical modifica-
tion of nucleic acids with PS molecules, illustrated for MPc, but which can
be easily extrapolated to Por, chlorin and BODIPY derivatives.
Fig. 18 BODIPY-labelled nucleoside triphosphate analogues suitable for
their use in polymerase-based methods such as primer extension (PEX) or
polymerase chain reaction (PCR). Reproduced with permission from
ref. 186. Copyright 2014 American Chemical Society.
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
A
ug
us
t 2
01
8.
  
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2018 Chem. Soc. Rev., 2018, 47, 7369--7400 | 7387
DNA interstrand cross-linking (Fig. 19). This approach leads to
covalently linked DNA duplexes with high stability, employed in
biosensing.204 Torres and co-workers explored in detail this
methodology, working with both Pc- and Por-based PS.205
5.2.2. DNA-based fluorescence diagnostic systems. DNA-
based fluorescence diagnostic systems are very useful at the
time of monitoring diﬀerent biological activities, including
those of enzymes,206 antibodies and other proteins.207 There
are indeed very good reviews in the literature about the use of
PS fluorescence for bioimaging.9,208 Therefore, herein we only
focus on the main examples involving the combination of PS
with an oligonucleotide, which are not many at all. The first
PS–oligonucleotide conjugates proposed for use in diagnostic
systems were reported by Hammer et al.,193 based on the
covalent linkage of various Zn(II)Pc compounds to the M13
primer through isothiocyanate chemistry. However, the authors
of this work did not test any real application. A more important
contribution to the field was then made by Nesterova et al., who
published the Zn(II)Pc–oligonucleotide conjugates (12a and
12b) for PCR fluorescence assays.191 The conjugates showed
water solubility and non-altered fluorescence emission, compared
to the free PS, which allowed utilizing them as primers for PCR
amplifications, and which could be detected and monitored by
near-IR fluorescence (Fig. 20).
5.2.3. Light-induced gene transfer. The delivery of DNA
inside cells can be light-induced (PCI), requiring the presence
of a PS that is able to destabilize the endosomal membrane.
Since the control of gene transfection in the body is a core issue
in gene therapy, this technique is of great interest in that field.
Kataoka and co-workers assessed in vivo DNA delivery in
2005 with the design of a ternary complex composed of a core
containing DNA packed with a cationic NLS peptide, enveloped
in an anionic dendritic Zn(II)Pc.209 The complex exhibited a
reduced photocytotoxicity and an important enhancement in
the transgene expression in vitro. This transgene expression was
shown to be highly selective in animal experiments, occurring
only at the irradiated site (Fig. 21). Some years after, in
2013, the same group published another study with the same
dendritic Zn(II)Pc, but in this case working with micelles
forming a multifunctional nanocarrier platform.210 In a diﬀerent,
Fig. 19 (a) General scheme of the interstrand cross-link (ICL) formation of
furan-modified DNA strands triggered by photooxidation. (b) Detailed ICL
mechanism. (c) Schematic representation of the diﬀerent PS employed for
this strategy. Adapted with permission from ref. 203. Copyright 2012
American Chemical Society.
Fig. 20 (a) Scheme of Zn(II)Pc derivatives 12a and 12b as labelling agents
in oligonucleotide PCR. (b) Images of agarose (left) and polyacrylamide
(right) gels after electrophoresis of PCR products. Detection was accomplished
using UV absorption at 254 nm after staining the gel with ethidiumbromide (left)
or near-IR fluorescence at 700 nm (right). Adapted with permission from
ref. 191. Copyright 2007 American Chemical Society.
Fig. 21 (a) Schematic representation of a plasmid DNA (pDNA)/quadruplicated
cationic peptide (CP4)/dendritic Zn(II)Pc (DPc) ternary complex preparation.
(b) Scheme showing the itinerary of this ternary complex for transgene
expression. The design of the ternary complex shows eﬀective control
over the initial steps (i.e. internalization by endocytosis of and photo-
damage to the endosomal membrane to release the polyplex to the
cytoplasm) in PCI-mediated gene delivery. Reproduced with permission
from ref. 209. Copyright 2005 Nature Publishing Group.
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covalent approach, chlorin e6 has been used for the transfection
of directly linked oligonucleotides by PCI, avoiding in this way
that the major fraction of the internalized oligonucleotides got
trapped in endosomes or lysosomes, which is usually the main
limit for their therapeutic potential.211
5.2.4. G-Quadruplex recognition. Among the countless nucleic
acid combinations present in Nature, guanine-rich sequences have
attracted great attention in recent decades. G-Quadruplex structures
involving G-quartets linked by loop oligonucleotides have shown
critical regulatory roles like DNA replication, transcription and
translation, among others.212,213
The literature about G-quadruplex biohybrids with Por and
Pc has been recently reviewed in a few review articles and,
therefore, it will not be fully covered herein.214–216 There are
only two additional remarkable examples. The first one is by
Zhang et al., who reported an extensive study where one BODIPY
derivative was selected among 5000 candidates to specifically bind
to parallel quadruplets, increasing its fluorescence quantum yield
(FF) from 0.014 to 0.28 when intercalated in such structure.
217
Kim and Kim also developed a BODIPY-labelled G-rich sequence
(50-BODUGGGTT-30), employed as a 30-overhang of telomeric
DNA, based on the formation of (3 + 1) intermolecular
G-quadruplexes.218
6. PS–carbohydrate biohybrids
The conjugation of PS to carbohydrates, including mono- and
disaccharides, oligosaccharides (e.g., cyclodextrins) and poly-
saccharides (e.g., cellulose, chitosan and dextran), is arguably
the most extensively explored strategy in order to obtain bio-
compatible photoactive materials. Carbohydrates improve the
aqueous solubility of PS and allow cellular recognition via
specific carbohydrate–protein interactions on cell surfaces,219,220
thus being able to provide specificity toward certain tumours.221
Compared to peptides, proteins and nucleic acids, there is not a
clear correlation between the type carbohydrate employed and the
biohybrid application, yet the combination of these biomolecules
with PS is normally directed to use in PDT, PDI and theranostics. In
any case, the structure of this section will be better based on the
distinction between, on the one hand, mono-, di- and oligo-
saccharides, which are molecularly well-defined; and, on the
other hand, polysaccharides, with very different structural,
nanoscopic and biological properties.
6.1. Biohybrids of PS with mono-, di- and oligosaccharides
Glycosylation of PS with mono- and disaccharides has been
performed extensively, and it was recently addressed in an
excellent and in-depth review by Drain and co-workers.222 The
following paragraphs will therefore focus only on cyclodextrins
(CD), as a particularly useful class of oligosaccharides. CD are
cyclic oligosaccharides composed of repetitive units of a-D-gluco-
piranose. Depending on the number of constituting monomers,
CD can be divided into a-CD (6 monomeric units), b-CD (7) and
g-CD (8). Diﬀerent hydrophobic molecules can be encapsulated
in the cavity of CD depending on their size.223 Furthermore, the
chemical and biological properties of guest molecules can be
modulated by encapsulation in this cages, while CD can be used
as nanocarriers in aqueous media.
The chemical modification of CD can be achieved in a
covalent or in a supramolecular way. A large variety of studies
have been published regarding the non-covalent association
between CD and PS, but most of them did not have a bio-
medical interest. Some examples of this supramolecular approach
include: the construction of supramolecular assemblies composed
of permethyl-b-CD, modified with perylene bisimides and Zn(II)Por
through the establishment of hydrophobic interactions,224 the study
of photoinduced electron transfer in complexes formed by a H2Por
and a b-CD containing viologen moieties,225 the inclusion of two
diﬀerent tetrasulphonated H2Por and Zn(II)Por compounds into the
inner cavity of BODIPY–b-CD conjugates, for the study of photo-
induced processes,226 the complexation of inorganic anions in
aqueous medium by an Fe(III)Por associated with b-CD,227 and the
encapsulation of H2Por within b-CD dimers,
228 among others.
A different approximation is the construction of supramolecular
structures from covalent conjugates between CD and PS, including
the formation of water-soluble nanospheres229 or nanowires.230 The
literature in this field is anyhow very extensive and it falls out of the
scope of the present review. Consequently, only the relevant cases
concerning biological applications will be discussed in the rest
of this section.
Although PS could be encapsulated in the inner cavity of CD,
the presence of hydroxyl groups in the structures of CD derivatives
provides the most useful anchor to perform the covalent grafting
of both kinds of molecules. In the case of Pc, for example, a b-CD
was covalently grafted onto 4-nitrophthalonitrile, through an ipso
substitution reaction, followed by crossed statistical condensation
with diﬀerent phthalonitriles, yielding asymmetrically substituted
Zn(II)Pc hybrids for the first time.231 Following a diﬀerent strategy,
through axial substitution, symmetrically and asymmetrically
substituted Si(IV)Pc (13a–13d) bearing one or two b-CD moieties
have been published for testing their photodynamic activity
against HT29 human colon adenocarcinoma andHepG2 human
hepatocarcinoma cells (Fig. 22).232 Besides Si(IV)Pc, a H2Por-based
conjugate has also been used for testing the photodynamic activity
Fig. 22 Structures of asymmetrically substituted Si(IV)Pc–b-CD derivatives
(13a–13d).
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against HT29 human colon adenocarcinoma cells, with similar
results.233
In 2014, Tome´ and co-workers evaluated the eﬀect that the
CD macrocycle size has on phototoxicity, specifically against
UM-UC-3 human bladder cancer cells, by studying three Zn(II)Pc
derivatives connected to a-CD, b-CD or g-CD.234 More recently, a
supramolecular Si(IV)Pc–b-CD hybrid was successfully applied to
the photoinactivation of antibiotic resistant bacteria.235 The
biohybrid preparation consisted of decorating b-CD vesicles
with a Si(IV)Pc carrying an axial adamantyl moiety, allowing
the incorporation in the vesicles via host–guest inclusion. As a
second axial substituent, a pyridinium moiety was employed to
provide good solubility to the Si(IV)Pc in aqueous media. Both
axial substituents also contributed to avoid H-type aggregation
in water, yet, according to UV-Vis data, J-type aggregation was
still present, decreasing the fluorescence and 1O2 production of the
Si(IV)Pc. Importantly, after complexation with the b-CD-vesicles,
reduced aggregation and an enhancement of those properties
could be observed in the conjugates.
Concerning other porphyrinoids, in 2006 Kra´l and co-workers
synthesized conjugates through covalent linkage of a fluorinated
H2Por with one or two b-CDs, and their PDT activity was tested in
diﬀerent lines of cancer cells.236 In vitro, the H2Por–(b-CD)1
complex showed a more lipophilic character, resulting in a
more efficient cellular uptake compared to H2Por–(b-CD)2.
Nevertheless, experiments in vivo showed that the latter conjugate
provoked a more effective photodynamic effect. The authors
suggested that the reason for this could be the possible association
of H2Por–(b-CD)2 with albumin or other serum proteins, allowing a
faster transport to tumour tissues, compared to H2Por–(b-CD)1,
which would associate with HDL due its more hydrophobic
character. A few years later, a new article by the same group
described four conjugates of H2Por and CD, with different
combinations and types of CD as substituents (Fig. 23).237 The
resulting hybrids were interesting agents not only for PDT but
also for chemotherapy, due to the ability of these CD moieties
to include different anticancer drugs in the inner cavity.
Fluorinated chlorins, in turn, have also been linked to b-CD,238
yielding conjugates with high water solubility and a good photo-
induced production of 1O2.
Liu and co-workers reported the synthesis of Por–CD conjugates
through a differentmethod, that is, by a Huisgen cycloaddition click
reaction between a triple bond-containing Zn(II)Por and an azide-
bearing b-CD.239 PDT experiments were not performed with these
conjugates, but the authors proposed further research to evaluate
their potential use as nanocontainers for drug delivery. More
recently, b-CD-derivatives have been linked to H2Por and Zn(II)Por,
and the resulting hybrids studied as possible modulators of the
aggregation of the amyloid beta (Ab) peptide, whose aggregates are
involved in Alzheimer’s disease. These complexes were able to block
the cytotoxic effect of Ab42 oligomers in human neuroblastoma cell
lines.240 Corrole derivatives have been linked to CDmacrocycles too.
In particular, 5,10,15-tris(pentafluorophenyl)corrole (TPFC) has been
linked to one or two units of b-CD (namely, b-CD1 and b-CD2), and
PDT experiments were carried out in HeLa cells. Both conjugates
showed the ability to produce 1O2, but still TPFC was the most
efficient 1O2 generator in this series of compounds.
241
Finally, concerning the supramolecular approach, intra-
cellular delivery of an anionic tetrasulphonated H2Por has been
achieved through its encapsulation into the inner cavity of
octaarginine–b-CD derivatives.242 Another example is the work
published by Kano and co-workers, relative to complex 15,
composed of a b-CD-dimer and an Fe(III)Por (Fig. 24). This
complex is a mimic of haemoglobin/myoglobin, with a hydro-
phobic region created around the iron center that allows it to
act as an antidote for cyanide poisoning.243
6.2. Biohybrids of PS with polysaccharides
6.2.1. PS–cellulose hybrids. Cellulose is the most abundant
biopolymer in the biosphere, and it has been processed
industrially for more than 150 years. In the last few decades,
nanotechnology has enabled the development of new high-end
cellulose derivatives. Rod-shaped cellulose nanocrystals (CNC),
for example, are attracting much attention due to their
excellent mechanical properties, high aspect ratio and surface
area, colloidal stability, biocompatibility and cheap processing
as a well-defined nanomaterial.244 In this respect, CNC are also
subjectable to be combined with PS, as shown in the next
paragraphs, with the resulting biohybrids benefiting from the
properties of both components in the area of biomedicine.
Fig. 23 (a) Structures of b-(g-)CD–H2Por conjugates (14a–14d). (b) Schematic
representation of the dual activity of the conjugates, where the CD unit can
host in the inner cavity cytostatic drugs, while H2Por acts as a phototoxic
agent. Adapted with permission from ref. 237. Copyright 2010 American
Chemical Society.
Fig. 24 Structure of the b-CD–Fe(III)Por complex (15), which mimics
haemoglobin/myoglobin and functions as an antidote for cyanide poisoning.
Adapted with permission from ref. 243. Copyright 2013 Wiley.
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Pc have been incorporated onto CNCmainly by supramolecular
means, in two diﬀerent examples that make use of electrostatic
interactions. In the first case, CNC bearing primary alcohol groups
were treated with (2,3-epoxypropyl)trimethylammonium chloride,
in order to obtain cationic groups on the CNC surface, onto which
negatively charged tetrasulphonated Cu(II)Pc was bound by a
synergy of electrostatic interactions and hydrogen bonding.245
The resulting biohybrid was used as a selective catalyst for the
oxidation of alcohols and alkyl arenes. In the second case, de la
Escosura and co-workers developed a method for the non-covalent
immobilization of octacationic Zn(II)Pc (16a and 16b) derivatives
onto the negative surface of sulphated CNC.246 These biohybrids
presented a strong PDI eﬀect against S. aureus, E. coli and
C. albicans. Importantly, the hybrids actually outperformed the
free Zn(II)Pc and all published related nanosystems that bear
the PS covalently attached to the cellulose surface (Fig. 25),
highlighting the utility and advantages of this new approach.
Regarding covalent hybrids, Chauhan and Yan performed
the synthesis of conjugates between CNC and BODIPY derivatives,
through sulphonamide linkages.247 The PS in this case was a
sulphonated BODIPY, covalently attached to CNC that were
previously modified to contain amino groups on their surface.
The resulting biohybrids were able to produce 1O2 upon irradiation,
but biological experiments were not carried out. 1O2-Producing
hybrids composed of nanocrystalline cellulose and H2Por or
Zn(II)Por were also developed by Carofiglio and co-workers,
through amide bond formation between an amino group of
the Por component and carboxylic acid groups from the CNC.248
Following a diﬀerent strategy, Krausz and co-workers grafted an
acetylenic Zn(II)Por into cotton, via click chemistry.249 The
obtained hybrid material showed good PDI activity against
E. coli and S. aureus. In 2011, the same approach was used by
Ghiladi and co-workers.250 The Zn(II)Por was functionalized with
a propargyl chain, and cellulose was modified with azide groups.
In this case, their PDI eﬃciency was tested againstMycobacterium
smegmatis, S. aureus and E. coli, obtaining the best results against
M. smegmatis and S. aureus. One year later, this study was
extended to get a better understanding of the mechanisms of
photoinactivation, and PDI activity was evaluated against other
microorganisms such as P. aeruginosa.251
6.2.2. PS–chitosan hybrids. Chitosan is a linear polysac-
charide composed of randomly distributed b-(1 - 4)-linked
D-glucosamine and N-acetyl-D-glucosamine. This polymer is made
by deacetylation of chitin, treating it with an alkaline medium,
like sodium hydroxide. Chitosan is easily modified in a physical or
chemical way, through covalent grafting or enzymatic modification.
Interestingly, the high biocompatibility, biodegradability and
permeability of chitosan, among others, render this biomaterial ideal
for manufacturing nanostructures, microspheres and hydrogels
with biomedical potential.252 Chitosan therefore represents a
promising scaffold to incorporate PS of different natures.
Ma´sson and co-workers published the synthesis of four
nanoconjugates composed of chitosan and amphiphilic chlorins
bearing an amino or a carboxyl group. To this end, they used
diﬀerent strategies and linkers, and experiments in tumour-
bearingmice showed good PDT results.253 Another synthetic strategy
involved the conjugation of chlorin e6 to iodinated chitosan.254 Apart
from the generation of 1O2 and the use of these conjugates for PDT,
they could be utilized as imaging agents, given that NIR fluorescence
signals from the cytoplasmwere detected after incubation withHeLa
cells. Photosensitizing nanoparticles made through the linkage of
glycol chitosan to pheophorbide a were also proposed.255
6.2.3. PS–dextran hybrids. Dextran is composed of a linear
chain of a-1,6-linked D-glucopyranose residues, with a-1,2-,
a-1,3- and a-1,4-linked side chains in low percentages. The
straightforward chemical modification of this biopolymer, due
to the presence of hydroxyl groups in its structure, and its good
properties for the development of nanomaterials, as in the case
of chitosan, make dextran a good PS carrier.256 Sortino and
co-workers reported, for example, a supramolecular hydrogel
built out of four components that included a polymer of b-CD,
dextran, a Zn(II)Pc and a nitric oxide photodonor.257 The generation
of 1O2 and nitric oxide by this complex was achieved after
irradiation with visible light, and so this formulation could be
used in PDT and PDI experiments. Dextran has been linked to
chlorin e6 too, by modifying the polymer with a cystamine
group, which could then be used to react with the carboxylic
acid group of the chlorin through amide bond formation.258 The
fluorescence of the resulting nanoparticles was higher than that
of chlorin e6 by itself. In experiments with HCT116 human colon
cancer cells, the hybrid also showed a higher cellular uptake,
ROS generation and phototoxicity. Importantly, this highly efficient
performance of the biohybrid could also be confirmed in vivo.
Fig. 25 (a) Chemical structures of 16a and 16b, as well as a schematic
representation of the supramolecular functionalization of CNCs. (b) Photo-
inactivation of S. aureus (left) and E. coli (right) upon red light irradiation
(620–645 nm; 18 mW cm2). The results are shown in blue for Zn(II)Pc 16a
and red for complex 16a–CNC. Reproduced with permission from ref. 246.
Copyright 2017 Wiley.
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From a diﬀerent perspective, the binding of dextran to
Mn(III)Por was carried out to test if linking the PS to dextran
could improve its properties as anMRI contrast agent.259 In this way,
the specific targeting of HepG2 cancer cells could be facilitated when
using this conjugate. Working also with Por, Sol and co-workers
reported in 2015 the synthesis of iron oxide nanoparticles covered
with dextran.260 Through the incorporation of azide moieties onto
these particles, the authors were able to attach diﬀerent hydrosoluble
Zn(II)Por derivatives, bearing a propargyl group, through click
chemistry reactions. They tested the phototoxicity of these systems
in human keratinocyte cells, evaluating the eﬀect of the number of
charges in the Por structure. The obtained results revealed that both
cationic and neutral nanoparticles were promising PS.
7. PS–liposome biohybrids
Liposomes are phospholipidic bilayer vesicles that present an
aqueous lumen within. The amphiphilic nature of phospholipids
results in their self-organization in aqueous solution, with the
polar head pointing toward the solvent and the aliphatic chains
forming the core of the bilayer shell. This distribution makes
them ideal delivery agents, due to the possibility of accommodat-
ing both hydrophilic and hydrophobic drugs in their inner cavity
or inserted in the hydrophobic bilayer, respectively (Fig. 26a and b).
This duality has been intensively employed in medical research and
clinical applications since the early 1970s.261 Also lipid composition,
size and charge have actually been extensively studied in the
literature, with the aim of enhancing the drug delivery performance,
including properties such as cellular uptake, circulation time and
passive recognition.262–264
The employment of liposomes for the encapsulation and
vehiculization of PS presents additional advantages.265 There is,
for example, no need to incorporate hydrophilic substituents in
the PS, due to the intrinsic lipophilic nature of the liposome
membrane.266 Moreover, the non-aggregated state of most PS
in membrane media allows maintaining intact their intrinsic
capacity for ROS generation, and their fluorescence, both in vitro
and in vivo.267 Some liposomes also possess the ability to deliver
PS in a controlled manner into the plasma membrane of cells,
resulting in an enhancement of phototoxicity,268 among other
interesting features. For all these reasons, many studies have
been focused on exploring diﬀerent aspects of the behaviour
of these carrier systems, as the involved mechanism in cell
death,269,270 or the determination of the most favourable lipidic
composition for their performance.271–273
Several groups have reported on PS–liposome hybrid systems
for different biomedical purposes, like imaging techniques,274
and PDT or PDI treatments of different cancerous cell lines or
tumours,275–281 leishmaniasis,282,283 Candida albicans,284 or
human chronic periodontitis,285 among others. More interestingly,
liposomes that enable the formulation of more than one active
component have recently attracted much attention, as they can
be employed as suitable platforms to render more complex
third-generation PS (Fig. 26). In particular, liposomes containing
PS have been combined with antibodies, other proteins or
peptides in ternary biohybrids that enhance the biological
selectivity and increase the PS cell penetration capacity. This is
currently the most interesting approach regarding the use of
liposomes for PS vehiculization, and so we will focus on it,
leaving out the traditional strategies for liposome formulation
of PS, which have been reviewed recently.265,286,287 Besides
antibodies, proteins and peptides, other types of materials
have been incorporated into ternary liposome–PS systems
but, due to their synthetic nature, fall out of the scope of the
present review.
7.1. PS–liposome–antibody biohybrids
Taking advantage of the outstanding biological selectivity conferred
by MAb, discussed earlier in this review, a few examples of ternary
hybrids consisting of PS-containing liposomes formulated together
with MAb have been described.
Early in 1989, Morgan et al. described the first example of Pc
compounds (i.e., a series of mono-, di-, tri- and tetrasulphonated
Al(III)Pc) encapsulated in liposomes, which were further coupled
to the 791T/36 antibody.288 The PDT eﬀect of these liposomes
was evaluated in two diﬀerent cell lines: osteosarcoma 791T and
colorectal carcinoma C170, as well in a control line bearing no
antigen (DW-BCL). Phototoxicity was observed against both
types of cells, and parameters such as the PS concentration,
the time of light exposure and the amount of cell antigens were
decisive in the obtained results. The same liposomal system was
later coupled to the polyclonal sheep anti-mouse-Ig antibody
and was employed to destroy target populations of cells in bone
marrow.289
Years later, Broekgaarden et al. described liposomes with a
bilayer made up of Zn(II)Pc molecules, functionally decorated
with single-domain antibodies directed against the EGFR, with
the objective of improving the delivery and selectivity of the
Fig. 26 Schematic representation of (a) hydrophilic PS encapsulated in
the inner cavity of a liposome, (b) hydrophobic PS inserted in the
membrane of a liposome, and (c) liposome formulation of two diﬀerent
active components, including targeting units at the periphery.
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PDT eﬀect of this Zn(II)Pc compound.290 In vitro studies with
EGFR-positive human epidermoid carcinoma (A431) cells and
EGFR-negative 3T3 2.2 murine fibroblasts eﬀectively demon-
strated a selective PS incorporation by EGFR overexpressing
cells, as determined by fluorescence spectroscopy and confocal
laser scanning microscopy. Further exposure to red light resulted
in a good phototoxicity, revealing increased PDT eﬃcacy as
compared to non-targeted liposomes, due to a higher and more
selective cell uptake combined with a redistribution of the
Zn(II)Pc molecules from the liposomes into diﬀerent intracellular
localizations, thus maximizing the PDT eﬀect.
With Por derivatives, Hasan and co-workers designed
another ternary liposome-based biohybrid that is able to target
epithelial ovarian cancer cells.291 This conjugate was composed
of 5,10,15,20-tetrakis(benzo[b]thiophene)–H2Por and the MAb
Cetuximab, which were associated in preformed plain lipo-
somes. The optical properties and the quantum yield efficiency
of the PS in the PICAL conjugate were more stable than for the
free PS. Ovcar-5 and CAMA-1 cell lines were used to study the
affinity of the conjugate to the EGFR, and the PS uptake was
higher when the amount of MAb was increased. The conjugate
also showed higher PDT efficacy than the PS by itself.
7.2. PS–liposome–protein biohybrids
Ngweniform et al. reported the co-assembly of Zn(II)Pc–liposome
hybrids with flagellar filaments, a type of protein nanotube
protruding from the surfaces of some bacteria.292 The Zn(II)Pc
was entrapped in the lipid bilayer of cationic liposomes, and the
flagella acquired a negatively charged surface by displaying an
anionic polypeptide on it. Consequently, a ternary biohybrid
arose from the assembly of the liposomes and the flagella
through electrostatic interactions. After the formation of
these complexes, an increase in the fluorescence intensity of
the Zn(II)Pc was observed, probably due to a reduction in its
vibrational motion. Following a similar strategy, Zn(II)Pc-loaded
cationic liposomes have been co-assembled with the M13
phage, a rod-like virus known to be able to carry drugs and
penetrate the blood–brain barrier without inducing toxicity or
obvious immune responses in human beings (Fig. 28).293 As in
the previous example, the formation of the ternary complex
resulted in an increase in the fluorescence intensity of the
Zn(II)Pc in the lipid bilayer. A preliminary study indicated
that the phage–liposome complex could be internalized in
breast cancer cells, making the phage–liposome–PS biohybrid
a promising PDT agent.
Likewise, the conjugation of tetrasulphonated Al(III)Pc lipo-
somes with human transferrin was evaluated in HeLa cells.294
Transferrin receptor levels are overexpressed in various cancers,
and so transferrin-decorated liposomes could be good candi-
dates for the delivery of PS in cancer therapy. The phototoxicity
of the hybrid was actually much higher than that of the free
Al(III)Pc, and the non-targeted Al(III)Pc–liposome system showed
poorer phototoxicity results. Based on such positive behaviour,
a complementary study was published in 2004 employing the
same approach for the PDT treatment of rat bladder carcinoma
cells.295
7.3. PS–liposome–peptide biohybrids
Apart from the abovementioned proteins, shorter peptide sequences
have also been used in the decoration of liposomes to target specific
tissues. Oku and co-workers, for example, published a study in
which benzoporphyrin derivative monoacid ring A (BPD-MA) has
been internalized in PEG-modified liposomes, decorated with
Ala-Pro-Arg-Pro-Gly (APRPG), a pentapeptide that is specific for
angiogenic endothelial cells.296 The resulting complexes showed
good results of phototoxicity after irradiation in tumoral cells.
The most interesting example regarding the combination of
peptides with liposomes for the delivery of PS, however, was
published by Lovell and co-workers in 2015. In their study, a Por
derivative containing a phospholipid (17-Co) was ensembled
together with dioleoylphosphatidylcholine (DOPC) to form a
bilayer of 100 nm diameter liposomes (Fig. 27a).297 Interestingly,
the presence of Co(II) chelated into the macrocycle allowed the
binding of peptides and proteins that carry a polyhistidine tag
(his-tag), endowing systems with very promising potential as drug
delivery systems. As proof-of-concept, the authors employed
his-tag RGD-targeting polypeptide-decorated liposomes, loaded
with sulphorhodamine B in their inner cavity. Biodistribution
assays visualising the cargo release demonstrated the specific
targeting of tumoral tissues in mice (Fig. 27b).
Fig. 27 (a) Schematic representation of the self-assembly of cationic
Zn(II)Pc-entrapped liposomes on the anionic genetically engineered phage
to form a rod-like phage–liposome complex. Structures not to scale. (b) TEM
images of stained engineered phages before (left) and after complexation with
Zn(II)Pc-loaded liposomes (right). Reproduced with permission from ref. 293.
Copyright 2009 Wiley.
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8. Other types of photosensitizing
biohybrid materials
8.1. Biohybrids of PS and steroid hormones
Steroids that act as hormones are also called steroid hormones.
As they are lipid soluble, they can pass easily through the cell
membrane and bind to steroid hormone receptors, bringing
about changes within the cell.298 Their linkage to PS is there-
fore of interest for biomedical applications,299 as we illustrate
with a few examples in the next paragraphs, focusing only on
the most representative cases of steroid hormones.
Cholesterol, for example, is a steroid hormone which is
essential for cell growth, as it is a key component of the plasmatic
and intracellular cell membranes.300 For this reason, easily
proliferating cancer cells are prone to take up more cholesterol
than healthy ones. Conjugating cholesterol to PS could therefore
result in biohybrids with increased cell uptake and photody-
namic eﬃciency. In 1994, Segalla et al. described the synthesis of
a Ge(IV)Pc conjugate with two units of cholesterol axially ligated,
which was then incorporated into liposomes for delivery, showing
a high phototoxic eﬀect in mice bearing an MS-2 fibrosarcoma.301
A diﬀerent grafting strategy was developed by Maree et al., who
prepared a Zn(II)Pc substituted with eight cholesterol moieties at
the periphery of the macrocycle.302 Unfortunately, the resulting
biohybrids showed a high tendency for aggregation and no
biological evaluation was performed. Other kinds of PS that
have been linked to cholesterol are pyropheophorbide303 and
chlorin e6,304 but in these cases the phototoxic eﬀect of the
conjugates was not evaluated in biological media.
Estradiol and estrone, on the other hand, are two of several
natural oestrogens, the primary female sex hormones. Breast
cancer cells are known to overexpress estrone and estradiol
receptors.305 Therefore, the design of PS–estradiol and PS–estrone
biohybrids constitutes a promising strategy to target breast cancer.
van Lier et al. explored this strategy by synthesizing Zn(II)Pc–
estradiol conjugates, employing the palladium-catalysed
Sonogashira reaction to couple estradiol to a monoiodo-Zn(II)Pc
via a 17a-ethynyl group.306 They also prepared Zn(II)Pc–estrogen
conjugates through spacers with an aliphatic or aromatic nature,
and trisulphonated Zn(II)Pc–estradiol conjugates, enabling a
comparison of their biological activities. The best phototoxic
effects were obtained with the sulphonated derivatives, whereas
the use of a spacer did not show any remarkable influence.
8.2. PS–folic acid biohybrids
Folic acid (FA) is an essential vitamin with an important role
in diﬀerent metabolic pathways, such as the biosynthesis of
nucleotides, and so it takes part in the proliferation of cells. Its
receptor, the folate receptor (FR), appears in an upregulated
way in cancer cells of ovary and kidney cancers, among others.
Consequently, the main advantages of the use of this molecule
for carrying attached drugs to cancer cells include the high
selectivity, combined with the achievement of high binding
aﬃnity, low immunogenicity and good biocompatibility.307
These advantages have also been used in a number of cases
for the conjugation to PS with applications in biomedicine.
Fig. 28 (a) Chemical structure of compound 17, and the liposome
assembling strategy. (b) Biodistribution of sulphorhodamine B delivered
by untargeted (black) and RGD-containing liposomes (red) 45 minutes
after intravenous injection into nude mice bearing subcutaneous U87
tumours. Adapted with permission from ref. 297. Copyright 2015 Nature
Publishing Group.
Fig. 29 (a) Chemical structure of compound 18. (b) Ultrafast protein liquid
chromatography (UPLC) of compound 18, detecting its elution time by UV
absorption and radioactivity. (c) In vitro stability of 18 in saline or serum
(10% FBS) solution. Reproduced with permission from ref. 310. Copyright
2011 Ivyspring Publishing Group.
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Herein we review a few of these cases, in order to illustrate the
potential of this strategy.
In 2008, Gravier et al. synthesized a conjugate composed of a
chlorin and FA, with an OEG motif as the spacer through an
EDC-mediated coupling reaction.308 The aim was to study the
PDT activity in KB tumours. Only the g-folate conjugate was used
for in vivo experiments, and it was found that both cell uptake
and tumour destruction increased with conjugation of the PS to
FA. Pyropheophorbide a, in turn, has also been linked to FA
through a pharmacokinetics modifying (PKM) peptide chain
prepared by Zheng and co-workers.309 A few years later, a
continuation of this work was carried out, in order to incorporate
64Cu in pyropheophorbide a (18), to convert the conjugate into a
PET imaging agent (Fig. 29).310 Finally, graphene oxide has been
loaded with FA and diﬀerent anticancer drugs, as a nanocarrier
platform to target human breast cancer cells.311 With chlorin e6,
bound to the nanoplatform through hydrophobic and p–p stack-
ing non-covalent interactions, the system showed good solubility
properties and a low cytotoxicity in experiments with MGC803
cells, suggesting it as a possible candidate for PDT.312
9. Summary and conclusions
In sum, the field of biohybrid materials has been merging in the
last few decades with that of PS, enabling the implementation of
a number of biomedical technologies with enormous future
impact. In a way, photosensitizing biohybrid materials represent a
new generation of PS systems, with improved features regarding
their behaviour in biological media. Importantly, the wide variety
of biomolecular structures available in Nature makes this
approach really versatile, allowing tuning the kind of biohybrid
depending on the aimed application or the target tissue. There are
also many methods available in the literature for the linkage,
either covalent or supramolecular, of synthetic PS to biomolecules
and their assemblies. The field is therefore now equipped with a
complete toolbox of building blocks and methodologies, which
ensures a fruitful growth in the coming decades, through an
explosion of possible combinations of PS molecules and bio-
molecules, presumably leading to novel PS uses. In this respect,
some new promising applications that are just starting to be
explored for light-induced nanomedicine include the use of PS
in phototherapy,62 biophotonics,313 and photoacoustic and thermal
theranostics.314 On these bases, and by further developing photo-
active biohybrids, scientists from disciplines at the crossroads
between chemistry, biology, nanomedicine and materials
science are taking major steps towards an eﬃcient biomedical
management of light.
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